Archives: BioMedWire

May 6, 2021 14:18:11

Predictive Oncology (NASDAQ: POAI) has made several advances in providing cancer treatment solutions. Its subsidiary, TumorGenesis, “specializes in technology that preserves a patient’s unique cancer tissue biological signatures, thereby allowing researchers to study cancer in the laboratory using samples that reflect actual tumors found in a patient,” reads a recent article. TumorGenesis’ transformational technology enables cell lines from patients to represent more than 90% of ovarian cancer cells, a significant improvement from the existing technologies, which can only represent 1% of ovarian tumor cells. “The result, simply stated, assists health providers in selecting the most effective drug to treat a specific patient’s unique cancer – personalized medicine at its finest.”

To view the full article, visit https://ibn.fm/SbOfh

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins, including vaccines, antibodies, large and small proteins and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Expansion of World-Class IP Portfolio

May 6, 2021 14:04:49

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it has entered into an amendment to a May 2020 license agreement with a major cancer research center in Houston, Texas, to grant to Genprex an exclusive worldwide license to an additional portfolio of six patents and one patent application and related technology (“newly licensed IP”). The newly licensed IP includes methods for treating non-small cell lung cancer (“NSCLC”) by administration of a TUSC2 therapeutic in conjunction with EGFR inhibitors or other anti-cancer therapies in patients predicted to be responsive to TUSC2 therapy. A TUSC2 gene-expressing plasmid is the active agent in Genprex’s lead drug candidate, REQORSA(TM). “We are pleased to continue optimizing and expanding our world-class intellectual property portfolio with the addition of these technologies,” said Rodney Varner, president and CEO of Genprex. “These new technologies further add to our arsenal of combination therapies for REQORSA and may enable us to improve patient outcomes through the advancement of multiple therapeutic approaches.”

To view the full press release, visit https://ibn.fm/h8ske

About Genprex Inc.

Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, REQORSA (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer. REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with AstraZeneca’s Tagrisso(R) (osimertinib) for patients with EFGR mutations whose tumors progressed after treatment with Tagrisso. For more information, visit the company’s web site at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) President to Present, Participate at Fifth International Vatican Conference

May 6, 2021 12:55:59

DarioHealth (NASDAQ: DRIO) president and North America general manager Rick Anderson will present at this year’s Vatican conference; the conference will be virtual this year. The Vatican’s Pontifical Council for Culture and the Cura Foundation’s Fifth International Vatican Conference is designed to globally advance human health by bringing together physicians, scientists, patient advocates, policy makers and other influential leaders from around the world. During the conference, which will be held May 6–8, 2021, participants discuss the latest breakthroughs in medicine, health care delivery and prevention. Anderson will be a featured presenter on the conference’s Insight and Perspectives track, as he discusses how technology can be used to support sustained behavior change and improve the health of people managing chronic diseases. DRIO is a pioneer in the global digital therapeutics market. Other conference speakers are Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases; Dr. Jane Goodall, founder of the Jane Goodall Institute and UN messenger of peace; and Jo Ann Jenkins, AARP CEO, and many others. Of particular interest is this year’s plan to launch a global #UnitedToPrevent campaign focused on the theme of Exploring the Mind, Body & Soul. The campaign will examine how innovations and novel delivery systems improve human health. “Technology available today offers a powerful alternative that combines the benefits of AI-based dynamic personalization, biofeedback and a digital delivery platform with the human touch and personal support people need to establish sustained behavior change,” said DarioHealth president and North America general manager Rick Anderson in the press release. “Digital therapeutic tools can provide greater health equity and access through asynchronous distributed care.”

To attend the conference, visit https://ibn.fm/UaTyU

To view the full press release, visit https://ibn.fm/BrI0q

About DarioHealth Corp.

DarioHealth Corp. is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. Dario’s next-generation, AI-powered, digital therapeutic solutions support more than just an individual’s disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions, intuitive, clinically proven digital tools, high-quality software and coaching to help individuals improve health and sustain meaningful outcomes. Dario offers one of the highest-rated diabetes and hypertension solutions on the market. The company’s cross-functional team operates at the intersection of life sciences, behavioral science, and software technology and is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users’ health. Dario makes the right thing to do the easy thing to do. For more information about the company, please visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Researchers Find Possible Cause of Silent Hypoxia in Coronavirus Patients

May 6, 2021 10:05:07

Researchers still don’t know a lot about the novel coronavirus and how it attacks various organs in the body. However, among the biggest mysteries of this disease is how it causes oxygen levels in an individual’s body to become abnormally low. This condition, usually referred to as silent hypoxia, irreversibly damages an individual’s vital organs if it remains undetected for an extended period of time.

With the help of computer models, biomedical engineers from Boston University have begun to get to the bottom of this mystery. Their study, which was reported in the “Nature Communications” journal, was conducted in collaboration with…

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Brain Scientific Inc. (BRSF) Eyes Plans for 2021 and Beyond

May 6, 2021 09:47:29

Commercial application of NeuroEEG and NeuroCap growing across ICUs, acute inpatient care and other emergency care in U.S.
BRSF plans to launch devices in Canada
Company expands footprint, plans patent applications in Latin America, Europe

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has unveiled the outlook for 2021. Brain Scientific continues to make strides within neurology by revolutionizing the brain diagnostic market with its groundbreaking technology. The company recently announced that its R&D efforts surged in 2020 with an investment of $275,926, which marks a 266% increase over 2019’s total of $103,616 (https://ibn.fm/Uiqs7).

Despite a challenging year due to the pandemic, Brain Scientific reached significant milestones in 2020. A limited-scope commercial application of the NeuroEEG(TM) and NeuroCap(TM) is in progress in the United States, expected to be…

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Centralized IRB Approval for Acclaim-1 Clinical Trial

May 5, 2021

May 5, 2021 11:18:20

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced its receipt of centralized Institutional Review Board (“IRB”) approval of the clinical trial protocol for its upcoming Acclaim-1 clinical trial in non-small cell lung cancer (“NSCLC”). Acclaim-1 is an open-label, multi-center Phase 1/2 clinical trial that combines the company’s lead drug candidate, REQORSA(TM) immunogene therapy, with AstraZeneca’s Tagrisso(R) (osimertinib) in patients with late-stage NSCLC with mutated epidermal growth factor receptors (“EGFRs”), whose disease progressed after treatment with Tagrisso. “The purpose of IRB review is to assure that appropriate steps are taken to protect the rights and welfare of individuals participating as subjects in clinical research,” said Rodney Varner, president and CEO of Genprex. “With this centralized IRB approval, we have achieved another significant clinical milestone. We remain focused on completing our preparations for the Acclaim-1 clinical trial and look forward to its commencement.”

To view the full press release, visit https://ibn.fm/Mcb4V

About Genprex Inc.

Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, “REQORSA(TM)” (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with AstraZeneca’s Tagrisso(R) (osimertinib) for patients with EFGR mutations whose tumors progressed after treatment with Tagrisso. For more information, visit the company’s web site at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Inks Distribution Agreement for Rapid COVID-19 Test Kits; Expands Commercial Leadership Team in Anticipation of Strong, Sustainable Sales

May 4, 2021

May 4, 2021 13:34:26

XPhyto Therapeutics Corp. recently announced it has entered into a distribution, storage and logistics agreement with a German distributor with an established network throughout Germany
Germany holds promise due to regulations requiring mandatory weekly testing for its citizens; this has the possibility of ramping up sales
Anticipating the increase in sales and distribution, XPhyto expanded its commercial leadership team by bringing on board Mr. Wolfgang Probst and Mr. Manfred Buchberger
Mr. Probst will be the company’s Chief Operations Officer (“COO”), while Mr. Buchberger will be the Head of Corporate Development at wholly owned subsidiary XP Diagnostics GmbH

The approvals XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) received in Europe back in March for the commercial production and use of its commercial 25-minute COVID-19 RT-PCR test system (“Covid-ID Lab”) (https://ibn.fm/UTfVU), set the ball rolling for events that would lead to a recent announcement.

On April 21, XPhyto, a life sciences technology accelerator, announced it has entered into a distribution, storage and logistics agreement with a full-fledged German pharmaceutical wholesaler and service provider, which will back the company’s efforts to launch sales in April (https://ibn.fm/65aYL). The German distributor will distribute, store, and deliver the Covid-ID Lab test kits to…

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Computer Analysis May Help Create Personalized Healthy Diets

May 4, 2021

May 4, 2021 12:50:45

A mathematical model developed by scientists from Sweden’s Chalmers University of Technology has been designed to help researchers create tailored diets and new probiotics to prevent illnesses. The lead author of the study, Prof. Jens Nielsen, explained that intestinal bacteria played a crucial role in the development of illnesses and the quality of an individual’s health and noted that the mathematical model would be very helpful in these areas. The study was reported in the “PNAS” journal.

The new study highlights the performance of the mathematical model in making predictions associated with a couple of prior clinical studies: one that involved adults…

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

RYAH Group About to Start Trading on Canadian Securities Exchange

May 4, 2021

May 4, 2021 10:06:20

RYAH Group to start trading on Canadian Securities Exchange following a transaction involving a triangular merger
RYAH Group is digital health care analytics and technology company developing innovative solutions for the plant-based medical industry
RYAH is poised for growth as the world transitions to remote health at an accelerated pace due to the pandemic

RYAH Group (formerly known as Prime Blockchain Inc.) will start trading on the Canadian Securities Exchange under the ticker symbol “RYAH” today (https://ibn.fm/Z6gZj). The New York-based digital health care analytics and technology company is focused on the development and commercialization of innovative technology, including software and hardware, for the plant-based medical industry. The upcoming listing follows the Company’s previously announced closing of a reverse takeover transaction with Potbotics Inc. The transaction included a triangular merger between RYAH Group (formerly Prime Blockchain, Inc.), Potbotics, and a wholly-owned Florida subsidiary of the Company incorporated to complete the… Read More>> NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Eyes Significant Market Opportunity

May 3, 2021

May 3, 2021 14:27:45

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, raised eyebrows when it announced that XPhyto Laboratories Inc., its Alberta subsidiary, added mescaline production to its psychedelic medicine development programs earlier this year (https://ibn.fm/cHwJi). Mescaline has begun attracting legislative attention, much like was the case with cannabis, which gained widening legalization as state after state approved varied uses of hemp and cannabis within their political boundaries. Recently, California Senator Scott Wiener introduced a bill that would decriminalize select hallucinogenics, including mescaline, in part due to research from top medical universities indicating that such substances can have significant benefits for treating mental health and substance use disorders. “The bill passed the Senate Health Committee by a vote of 6-1 on April 14 and will now be reviewed by the Senate Appropriations Committee,” reads a recent article. “We see a significant market opportunity in the production of pharmaceutical mescaline and the standardization of dosage formulations with precise, predictable and efficient drug delivery for clinical study and therapeutic use,” XPhyto CEO and Director Hugh Rogers said in the company’s announcement. “Our goal is to develop industrial scale production processes for the wholesale market and for incorporation into XPhyto’s thin film drug delivery platforms.”

To view the full article, visit https://ibn.fm/bcEDH

About XPhyto Therapeutics Corp.

XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. These include precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about the company, visit www.XPhyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

DGE’s 4th Virtual Clinical Trials Conference

May 3, 2021

May 3, 2021 13:56:44

Monday, May 17, 2021

On Monday, May 17th, 2021, pharma companies, medical vendors, and clinicians are invited to attend the 4th Virtual Clinical Trials conference – the industry’s leading, longest-lasting conference on virtual clinical trials. The event is hosted by Dynamic Global Events (“DGE”), a Life Science Leader in organizing B2B Events. The global event company caters to the dynamic informational and networking needs of the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries.

On May 17-18^th The 4th Virtual Clinical Trials will increase your ability to execute your decentralized trial, reduce site visits, accelerate timelines and gather data faster. Hear from top industry experts that will…

For tickets to the event, please visit https://ibn.fm/QduhD

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Researchers Find That Disrupted Sleep Could Result in Early Death

May 3, 2021

May 3, 2021 10:42:58

A recent study has found a clear link between a higher risk of dying from illnesses of the heart and blood vessels and the duration and frequency of unconscious wakefulness throughout night-time sleep.

The researchers discovered that in comparison with the general female population, women who underwent unconscious wakefulness for long periods of time had a higher risk of dying from a cardiovascular ailment. The research findings…

NOTE TO INVESTORS: The latest news and updates relating to Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Is ‘One to Watch’

April 30, 2021 13:04:14

Tryp Therapeutics is a pharmaceutical company with a focus on developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways
The company currently has two drug candidates in development: TRP-8802 (targeting fibromyalgia, eating disorders and chronic pain conditions); and TRP-1001 (targeting soft tissue sarcomas)
Through its PFN(TM) program, the company is focused on developing psilocybin-based drug therapies for certain neuropsychiatric disorders that offer increased efficacy and reduced risk of abuse or addiction
The company’s management team has decades of experience in the life sciences industry, including the pharmaceutical and biotechnology markets
Oncology therapeutics are expected to account for roughly 30% of all drug sales by 2024, representing a total market valued at approximately $200 billion

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways.

The company was founded in 2019 and is headquartered in…

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

United Medical Equipment Business Solutions Network Inc. Provides Solutions for Safer Workplaces

April 30, 2021 12:43:01

Routine virus testing is effective overall employer strategy for providing employee safety and business continuity
More research needs to be done on how long vaccines are effective, if booster shots will be needed
Only 26% of the U.S. is fully vaccinated; vaccinated individuals can still spread the virus

United Medical Equipment Business Solutions Network provides solutions that fit the ever-changing needs of the nation’s workforce during the COVID-19 pandemic through the distribution of rapid antigen tests and COVID-19 rapid kit testing. As employers begin to reopen worksites, routine virus testing is an effective overall strategy for providing employee safety and business continuity.

Chief medical advisor to the president Anthony Fauci, MD, has stated that booster shots for COVID-19 may be needed (https://ibn.fm/NWcBr). The vaccines currently being offered are said to provide protection for at least six months, but more research needs to be…

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Offering Cost-Effective, Efficient BCI Solutions

April 30, 2021 11:12:41

Brain Scientific (OTCQB: BRSF), focused on modernizing the brain diagnostic market through cutting-edge technologies, has created two FDA-cleared products (the NeuroCap(TM) and NeuroEEG(TM)) that are nothing like other brain-computer interface (“BCI”) solutions in the market. It has been observed that “data collected from consumer-centric, low-cost BCIs are typically not as efficient or as pristine as that retrieved from research-grade conventional wired EEGs (electroencephalograms),” notes a recent article. “Many of the BCIs on the market are not gelled so that the consumer can easily fit the product themselves. They have far fewer electrodes and are designed for the ease of the consumer rather than the researcher. Brain Scientific is different… the company provides a cost-efficient, pre-gelled, disposable and wireless solution that provides the same signal quality as the traditional wired EEG.”

To view the full article, visit https://ibn.fm/vd9sq

About Brain Scientific Inc.

Brain Scientific is a commercial-stage health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Researchers Find Brain Damage in Coronavirus Patients

April 30, 2021 10:13:28

New research conducted by neuroradiologists, neurologists and neuropathologists from the Vagelos College of Physicians and Surgeons, Columbia University, has found that the virus that causes the coronavirus, the SARS-CoV-2, also causes considerable neurological damage to a patient’s brain.

Study lead James E. Goldman stated that there has been a weighty debate about whether the ailment infects the brain. However, the study, which he conducted with assistant professor of neurology Kiran T. Thakur and professor Pater D. Canoll, who specializes in pathology…

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment Business Solutions Network Inc. are available in the company’s newsroom at https://ibn.fm/UnitedMed

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

New Study Finds That Generations X, Y Display Poorer Health Trends

April 29, 2021 14:15:07

According to a recent study, Gen X and Y are demonstrating higher levels of unhealthy behaviors and poorer physical health, in comparison with older generations. The study was reported in the “American Journal of Epidemiology” on March 18, 2021.

Since the 21st century begun, mortality and morbidity has been growing among younger and middle-aged Americans. Researchers from the Ohio State University, Columbus looked into these unfavorable trends to discover whether they extended to the younger generations…

NOTE TO INVESTORS: The latest news and updates relating to Predictive Oncology (NASDAQ: POAI) are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Continues to Strengthen Position in Plant-Based Health Industry

April 29, 2021 13:06:14

Healthy Extracts (OTCQB: HYEX) is committed to growth and has aligned its operations to focus on the plant-based health industry. Reflecting this focus, HYEX changed its name from Grey Cloak Tech to align with the company’s objectives and a “Live Life Young Again” strategy. “The company is making remarkable strides to strengthen its market positions in the plant-based health industry through its two key subsidiaries, the science-based BergaMet North America and Ultimate Brain Nutrients (‘UBN’),” reads a recent article. The company also achieved significant accomplishments in 2020, including a 71% increase in recorded gross revenue, despite the COVID pandemic, as well as elimination of all convertible debt. Further, net shareholder equity increased by $3.7 million. With regards to plant-based products, HYEX introduced “Clinical Immune, a clinically proven immunity product focusing on heart and respiratory health, while sales of the Fuel4Thought Brain Booster product are expected to begin in Q2 after completion of key clinical studies.”

To view the full article, visit https://ibn.fm/D8z7m

About Healthy Extracts Inc.

Healthy Extracts serves as a platform for developing and acquiring complementary companies that feature science-forward, clinically proven, plant-based and proprietary products in select high-margin and high-growth categories within the multibillion-dollar nutraceuticals market – the first two multimillion-dollar examples of which have already been launched. Company subsidiaries BergametNA(TM) and Ultimate Brain Nutrients(TM) (“UBN”) are providers of nutraceutical natural heart and brain health supplements, including the only heart health supplement containing Citrus Bergamot SuperFruit(TM), the highest quality and concentration of polyphenols and flavonoids available anywhere in the world and exclusive to BergametNA in North America and backed by 17 clinical studies. UBN’s KETONOMICS(R) proprietary formulations improve brain health, including memory, cognition, focus and neuro-energy, and have multiple intellectual property license opportunities for monetizing the company’s portfolio. UBN has six unique formulation patents — two issued and four pending. For more information, visit: www.HealthyExtractsInc.com, www.BergametNA.com or www.Fuel4Thought.com.

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – RYAH Group Inc. Featured in Bell2Bell Podcast

April 29, 2021 12:46:43

RYAH Group, engaged in the development and commercialization of various innovative technology solutions for the plant-based medical industry, was featured in The Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. RYAH’s CEO Gregory Wagner joined the latest episode to discuss the company’s 2021 goals and milestones, as well as provide an overview of RYAH’s business model and product offerings. “I came to the company two years ago, and the reason why I came here from a different career was because I was completely floored by the amount of data this company had been collecting over years in plant-based medicine,” Wagner said. “Essentially the company’s mission is both devices and data. I like to think of the company as a pioneering IoT device and digital care platform. We’re designed to capture complex datapoints to better enable doctors and clinics to create highly customized, personalized dosing regiments… and also to help governments make better regulatory decisions around plant-based medicine based on the data that we can provide and hopefully, eventually, encourage Big Pharma to make medical breakthroughs in plant-based medicine with our data analytics.”

To view the full press release, visit https://ibn.fm/PxM4j

About RYAH Group Inc.

RYAH is a company operating out of New York, which, directly and through its wholly owned subsidiary RYAH Medtech Inc., is engaged in the development and commercialization of various innovative technology solutions (both software and hardware) for the plant-based medical industry. Since its formation, RYAH Group has been focused on leveraging its know-how in predictive analytics to pioneer products to be used within its suite of vertically integrated technologies to provide users with added control over their health and wellness. As an emerging company, RYAH is striving to establish itself as a leader in delivering innovative, user-friendly IoT devices in the plant-based medical industry. By utilizing its know-how in fields such as artificial intelligence and predictive analytics, the company is moving towards building a portfolio of vertically integrated products that facilitate harmonized data collection throughout the complete medical plant lifecycle, from seed to consumption. For more information about the company, please visit www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Ryah Group Inc. Uses Big Data, AI to Reshape Plant-Based Medicine

April 29, 2021 11:15:18

RYAH recognizes the value data combined with analytics can bring to almost every industry.
Company focused on becoming a technological leader in the plant-based treatment market.
RYAH’s easy-to-operate line of products help foster a seamless dose-control experience that generates insightful data.

A recent Forbes article called it the “oil” of the fourth industrial revolution (https://ibn.fm/x7inY) while a Gartner article noted it was a core function for businesses focused on success in 2021 (https://ibn.fm/wQ1Ht). Whatever it is called, data has become a hot commodity in today’s world, and the RYAH Group is dedicated to transforming patient care through big data and AI to unearth breakthrough discoveries that will reshape understanding of plant-based medicines.

“Self-driving cars, lifelike robots, and autonomous delivery drones are the sexy, headline-grabbing face of the digital transformation that we see all around us today,” stated the “Forbes” article. “None of these would be…

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Burgeoning Plant-Based Health Products Market Holds Promise for Healthy Extracts Inc. (HYEX)

April 29, 2021 09:30:21

Healthy Extracts Inc. engages in proprietary R&D, sales and distribution of health products through its BergaMet North America and Ultimate Brain Nutrients (“UBN”) subsidiaries
The global brain health supplements, UBN’s domain, is projected to grow at a CAGR of 8% from 2021 to 2028
The global heart health supplements market, BergaMet’s segment, is expected to witness a CAGR of 4.5% from 2020 to 2030
Overall, the global botanical and plant-derived drug market will potentially expand at a CAGR of 6.1% from 2017 to 2022

According to projections by various research firms, the global health products market is expected to continue growing well into the late 2020s. The studies cite increased interest among consumers who are now adopting preventive care to help them maintain a healthy life, with higher availability of health products for the specific needs of consumers, and the ease with which they can access the said products, as some of the factors behind the growth.

The latter two growth drivers touch on the operations and focus of…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Researchers Identify Human Genes That Fight SARS-CoV-2 Infection

April 28, 2021 12:46:50

Researchers have determined which set of human genes help fight the infection that is known to cause COVID-19, the SARS-CoV-2. This information could be beneficial in helping researchers understand the factors that influence the ailment’s severity, in addition to assisting in the formulation of therapies for the said disease. The research was reported in the “Molecular Cell” journal.

The genes, which were identified by researchers from the Sanford Burnham Prebys Medical Discovery Institute are associated with the cells that fight…

NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Pursues Market Access in Israel for ‘Covid-ID Lab’

April 28, 2021 09:19:41

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced that it has delivered 2,000 of its rapid 25-minute PCR tests (“Covid-ID Lab”) to an established medical distributor in Israel for clinical evaluation of Covid-ID Lab for the purpose of commercial regulatory approval and potential product distribution. According to the update, the Israeli distributor markets and distributes a range of medical products and diagnostics in Israel and surrounding Middle Eastern countries. Its customers include government and private institutions such as hospitals, pharmacies and a broad range of health care providers. “We are excited by the opportunity to expand potential distribution beyond Germany. We are building strong partnerships around the world and Israel is a leading nation for COVID-19 management and research,” said Hugh Rogers, CEO and director of XPhyto. “We expect that rapid and accurate diagnostic testing will remain a primary tool for pandemic management and monitoring for many years to come.”

To view the full press release, visit https://ibn.fm/6WWHH

About XPhyto Therapeutics Corp.

XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. For more information visit the company’s website at www.Xphyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Technology Development is at the Forefront of Bladder Cancer Visualization Innovation

April 28, 2021 09:03:28

The i/Blue Imaging System’s(TM) development is the first to harness the power of white light and blue light visualization techniques with the added capability of displaying multiple images simultaneously which will help surgeons perform more accurate tumor resections
Imagin Medical’s innovative system is currently in the manufacturing phase with Lighthouse Imaging with product completion slated for 2022
With its patented technology, the company is positioned to stake a claim on a $400 million segment of the $46 billion global endoscopy market

Advancements in the way that cancer is diagnosed and treated continue to be made. On the forefront of new technological innovation for visualizing cancer is Imagin Medical (CSE: IME) (OTCQB: IMEXF) i/Blue(TM) Imaging System, a technology designed to combine the advantages of traditional white light with blue light imaging to provide unparalleled visualization for removal of bladder cancer.

Bladder cancer is the sixth most prevalent cancer found in the United States and has one of the highest recurrence rates. The American Cancer Society estimates there will be…

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – RYAH Group Inc. to Begin Trading on CSE under RYAH Ticker

April 28, 2021 08:43:53

RYAH Group (formerly known as Prime Blockchain Inc.) has announced that, beginning Tuesday, May 4, its common shares will begin trading on the Canadian Securities Exchange (“CSE”) under the ticker symbol RYAH. In accordance with CSE policies, the company has filed the required listing statement on SEDAR. RYAH just recently closed a reverse takeover transaction of Potbotics Inc., consisting of a triangular merger between the company (formerly Prime Blockchain, Inc.), Potbotics and a wholly owned Florida subsidiary of the company. “This is another major step in our journey in transforming patient care through our remote, connected devices and data analytics, to help unearth breakthrough discoveries that will reshape our understanding of plant-based medicines, nutraceuticals and beyond,” said RYAH CEO Gregory Wagner in the press release. “We continue to live our mission and vision of delivering cutting-edge innovation to advance digital care and to provide shareholder and consumer value in all of our products and services.”

To view the full press release, visit https://ibn.fm/bRSK6

About RYAH Group Inc.

NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics Featured in DojoLIVE! Interview

April 27, 2021 14:10:34

Predictive Oncology’s (NASDAQ: POAI) subsidiary company, Helomics, was recently featured on DojoLIVE!, an engaging podcast and interview forum that brings together technology, business and thought leaders from a wide range of industries. The company’s Chief Technical Officer, Mark Collins, PhD, joined the interview to discuss what Helomics is bringing to the table in the field of cancer research in the podcast titled “Can We Cure Cancer with Artificial Intelligence?” “At Helomics, we have a nice convergence of data that we’ve gathered from testing live tumors, tumors outside the patient body, on drugs, standard of care drugs, normal drugs that you might get if you were diagnosed with cancer,” he said. “We have a massive collection of data that goes along with that drug response — over 150,000 tumors, which is a huge data set. And, then again, we have AI. And it’s that convergence of AI, the big data if you will, and the biology that means we’re able to test drugs on living tumor tissue rather than some artificial system that is really what’s driving what we do.”

To view the full article, visit https://ibn.fm/wN4qq

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Stanford Team Finds AI to Safely Include Study Subjects Who Could Have Been Ruled Out Previously

April 27, 2021 14:07:49

A group of scientists from Stanford University in collaboration with Genentech, a biotechnology corporation, has created a system based on AI that can be used to safely add participants to clinical trials that they may have previously been barred from. The group’s findings were reported in the “Nature” journal, with Columbia University’s James Rogers and Chunhua Weng publishing a “News & Views” piece on the group’s research in the same journal.

Many countries have put in place measures to ensure that all drugs undergo clinical trials before being approved for use by patients in order to demonstrate that, in addition to being…

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Board Appointment of Dr. Joanne Curley

April 27, 2021 13:07:07

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the appointment of Joanne Curley, Ph.D. to its board of directors. VistaGen’s board will be comprised of seven directors following Dr. Curley’s appointment. “Joanne brings more than 25 years of pharmaceutical industry experience across numerous key operational and therapeutic areas,” said Shawn Singh, chief executive officer of VistaGen. “Her track record of propelling seven products from early development through regulatory approval is impressive and reflects her extensive experience and understanding of the entire life cycle of drug development. As we expand our business and pursue our mission to improve mental health and well-being for individuals in the U.S. and abroad, her tremendous leadership, creativity and expertise will be invaluable to VistaGen.”

To view the full press release, visit https://ibn.fm/HFj1t

About VistaGen Therapeutics Inc.

VistaGen is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on Twitter, LinkedIn and Facebook.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Brain Scientific Inc. (BRSF) Receives FDA Clearance for Next-Gen NeuroCap

April 27, 2021 09:40:11

BRSF announced it has FDA clearance for next-gen NeuroCap
The newest version of the NeuroCap has added velcro strips, expanded size range to include pediatrics
New device can stay on the patient’s head for up to four hours

Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company, announced it has received clearance from the FDA for its next-generation NeuroCap(TM) (https://ibn.fm/RYmMH). This device is an advanced electroencephalogram (“EEG”) electrode array used in routine clinical and research settings. Like the previous version, the newest version of the NeuroCap will help improve patient access to neurological care through its simplicity, cost efficiency and one-time use. However, the next-gen version comes with a few upgrades.

“We are constantly working on new products for the EEG market,” stated Irina Nazarova, marketing director at Brain Scientific. “In the new version of NeuroCap, we added velcro strips for better adhesion. We also expanded the…

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

DGE’s Women’s Executive Leadership Virtual Workshop 201 to Empower Leaders to Build Teams that Deliver Superior Results

April 26, 2021 13:42:48

May 10, 2021

Virtual Event

Event Highlights

The Women’s Executive Leadership Virtual Workshop 201 is an event designed for mid-level and senior leaders.
The event scheduled for May 10 is meant to empower leaders to consider the input of the teams they oversee and build teams that can deliver exemplary results.
The speaker, Colleen Hauk, is a seasoned trainer and leader with experience spanning 15 years.

Described as relatable, dynamic, passionate, and inspirational, Colleen Hauk – the event’s speaker – has made a name for herself as a seasoned trainer, speaker, and co-author of two books. Colleen always seeks to empower her audiences and clients to expand their minds beyond what is expected so that they can strike a balance between leadership and their personal lives. She has delivered trainings and keynotes to various renowned organizations, including Panasonic, Dell, Coldwell Banker, US Foods, and more (https://ibn.fm/qTNlQ).

With a 15-year career spent in the corporate landscape, Colleen excelled at bringing transformation by incorporating smart solutions to combat business challenges, as well as inspiring those around her to…

For more information and to register, visit the event’s web portal at https://dgevents.com/event/womens-executive-leadership-virtual-workshop/

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – InnerScope Hearing Technologies Inc. (INND) Announces LOI to Launch a Subscription-Based App

April 26, 2021 13:25:46

InnerScope Hearing Technologies (OTC: INND), an emerging and disruptive leader in the direct-to-consumer hearing device and hearing health technology space, has signed a letter of intent (“LOI”) with Audio Cardio Inc., dba AudioCardio(TM). The agreement provides InnerScope with a worldwide license, except for Japan, Korea and China, for full commercial rights to develop, market and sell an InnerScope-branded, subscription-based mobile app utilizing AudioCardio proprietary software. The software includes the clinically proven Threshold Sound Conditioning technology. The proposed transaction outlined in the agreement provides for both InnerScope and AudioCardio to achieve greater market penetration by focusing on enhancing the visibility and awareness for Threshold Sound Conditioning Therapy in treating several different things, including sensorineural hearing loss and tinnitus due to otoacoustic trauma. InnerScope plans to market the Hearing Therapy App with options of monthly, semiannual and annual subscriptions. “We are thrilled to have the opportunity to utilize AudioCardio’s proprietary software, including their clinically proven Threshold Sound Conditioning technology for InnerScope’s Hearing Therapy App,” said InnerScope Hearing Technologies CEO Matthew Moore in the press release. “We are very excited about entering into the mobile subscription-app space, giving InnerScope greater capabilities for growth and revenue potential. With AudioCardio’s help and its technology, InnerScope, through its Hearing Therapy app, will be able to reach a more significant number of people around the world with untreated hearing loss by offering a proven hearing treatment using only their smartphone. The Hearing Therapy App would also give InnerScope visibility to offer its potentially hundreds of thousand subscription customers who might need or want InnerScope’s Affordable Direct-to-Consumer Rechargeable App-Controlled Self-Adjusting Hearing Devices or other InnerScope Hearing Health Products.”

To view the full press release, visit https://ibn.fm/L9kRt

About InnerScope Hearing Technologies Inc.

InnerScope Hearing Technologies is a manufacturer, distributor and retailer of FDA-Registered direct-to-consumer (“DTC”), app-controlled, self-adjusting hearing aids; app-controlled, self-adjusting personal sound amplifier products; doctor-formulated dietary hearing and tinnitus supplements; and other ear and hearing health-related products. The company’s mission is to improve the quality of life of the 70 million people in North America who suffer from hearing impairment and/or hearing-related issues. INND’s management team applying decades of industry experience and believes the company is well positioned to directly benefit from the Over-the-Counter Hearing Aid Act, which is expected to be enacted within the next few months. InnerScope with its affordable app-controlled, self-adjusting hearing technology combined with its innovative point-of-sale hearing screening kiosks are designed for consumers with mild-to-moderate hearing loss to purchase over-the-counter hearing aids without being seen by a hearing care professional. For more information, please visit www.INND.com.

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Advancing i/Blue(TM) Imaging Solution

April 26, 2021 12:15:32

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is advancing its proprietary and patented i/Blue(TM) Imaging System. Imagin’s goal is to reduce the cost of treatment for patients with bladder cancer while also improving their chances of survival. Its solution “advances the blue light procedure by allowing surgeons to see the bladder wall under both white and blue light simultaneously in side-by-side presentation, whereas existing systems require surgeons to toggle back and forth between white and blue during the course of the procedure.” According to an article detailing this matter, the existing systems have proven disadvantageous because they increase the likelihood of underestimating the size of the tumor. Fortunately, the i/Blue Imaging System solves this problem. Also, the crucial turning point is imminent as “Imagin is advancing toward manufacturing and FDA approval of its solution.”

To view the full article, visit https://ibn.fm/pTtwp

About Imagin Medical

Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i/Blue(TM) Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The company’s initial focus is bladder cancer. For more information about the company, visit www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc. Offers Unique Mobile Solution

April 26, 2021 11:54:17

United Medical Equipment (“UME,” “UMEBSNI”) has committed to help speed economic recovery by supplying rapid COVID-19 test kits. In addition, the company has even gone a step further by offering “a unique mobile solution that involves on-call onsite COVID-19 Rapid Testing Mobile units,” reads a recent article. This offering is regarded as essential during the pandemic. “These units involve mobile testing specialists and experienced medical staff members who provide onsite COVID-19 rapid testing. Capable of nationwide deployment for extended periods, they are especially beneficial for securing employee safety.”

To view the full article, visit https://ibn.fm/5n61f

About United Medical Equipment Business Solutions Network Inc.

United Medical Equipment Business Solutions Network offers reliable resources and solutions that are designed to meet the ever-changing needs of an aging population, which includes seniors and veterans. The company’s owners and founders bring decades of combined business, military and cardiovascular critical care nursing experience. United Medical Equipment understands the needs and concerns of the aging population, including veterans and their families, and offers the support, solutions and reliable information critical in making informed decisions. UMEs’ mission is to provide guidance for caregivers, veterans, the aging population and medical community through its medication management and telehealth applications by providing reliable resources, products and support services designed to meet unique needs. For more information, visit the company’s website at www.UnitedMedSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to UME are available in the company’s newsroom at https://ibn.fm/UnitedMed

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Korean Researchers Develop Tech That Predicts Kidney Cancer Recurrence

April 26, 2021 10:36:58

A team of researchers has designed AI software that can forecast the recurrence of kidney cancer. The researchers, who are all from St. Mary’s Seoul Hospital, were led by Department of Urology Prof. Hong Seung-hoo. The research findings were reported in the “JMIR Medical Informatics” journal.

The proposed algorithm can be used to forecast the probability of kidney recurrence five to 10 years after surgeries have been performed. It can predict this through…

NOTE TO INVESTORS: The latest news and updates relating to Healthy Extracts Inc. (OTCQB: HYEX) are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Dynamic Global Events’ KOL & Thought Leader Engagement Summit April 28th -29th, 2021

April 23, 2021

April 23, 2021 10:36:39

Industry professionals are invited to attend the KOL & Thought Leader Engagement Summit, hosted by Dynamic Global Events (“DGE”), a Life Science Leader in organizing B2B Events. The Global Event Company caters to the dynamic informational and networking needs of the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries.

The event timings on the first day are 8:30 am – 5:00 pm. The next day’s timings are 8:30 am – 4:15 pm, concluding the event with a discussion on the…

To register for this event, please visit https://ibn.fm/IT1sy

To receive a discount on your registration, please use code IBN2021.

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Brain Scientific Inc. (BRSF) Joins Forces with JelikaLite to Reduce Symptoms of Autism

April 23, 2021

April 23, 2021 09:41:39

BRSF and JelikaLite have joined forces in a clinical trial for reducing autism symptoms in children
JelikaLite uses PRM therapy to reduce autism symptoms
BRSF sees this as an important step forward in wider adoption of affordable, accessible EEG systems

The neurology-focused medical device and software company Brain Scientific (OTCQB: BRSF) announced on March 16, 2021, it is collaborating with JelikaLite in a clinical trial. The clinical trial, which began in March 2021, is designed to potentially uncover new treatment options to reduce autism symptoms in children. The trial has 30 participants from two New York City locations.

JelikaLite was launched by medical researchers and practitioners specializing in psychology, neurology and phototherapy. The company has developed an innovative solution to potentially reduce autism symptoms and is developing a home-based system that combines a…

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Set to Start Potentially Pivotal Berubicin Trial

April 22, 2021

April 22, 2021 13:58:06

CNS Pharmaceuticals (NASDAQ: CNSP) is working to determine the efficacy of its lead drug candidate, Berubicin, for the treatment of glioblastoma multiforme (“GBM”), an aggressive type of brain cancer for which there is currently no cure. Promising results were demonstrated when another company completed a small Phase 1 trial well over a decade ago in which 44% of patients saw their disease stabilize or improve. One Berubicin patient was living cancer-free as of the most recent medical assessment in November, nearly 15 years after the Phase 1 trial (https://ibn.fm/JnFSS). “CNS now hopes to advance Berubicin to commercial production, with the start of its potentially pivotal clinical trial slated to begin this quarter,” reads a recent article discussing the novel anthracycline that appears to cross the blood-brain barrier. “The global trial will compare Berubicin’s response to the effectiveness level of established chemotherapy drug lomustine in 243 GBM patients at about 35 clinical sites in the United States (https://ibn.fm/Wo3d9) and 25 more in foreign locations.”

To view the full article, visit https://ibn.fm/dc2vV

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Researchers Find Antioxidants That Can Help Prevent Cancerous HPV Infection in Women

April 22, 2021

April 22, 2021 13:46:35

A study conducted by a group of researchers from the Louisiana State University School of Public Health and Medicine, led by professor of biostatistics Hui-Yi Lin, has discovered that sufficient levels of five antioxidants may decrease infection with the human papilloma virus (“HPV”) strains that are linked to the development of cervical cancer.

Their research was reported…

NOTE TO INVESTORS: The latest news and updates relating to AzurRx BioPharma Inc. (NASDAQ: AZRX) are available in the company’s newsroom at https://ibn.fm/AZRX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Achieves Critical Step Toward Commercial Sales of ‘Covid-ID Lab’

April 21, 2021 14:41:55

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced its entry into an agreement with an established German pharmaceutical wholesaler and service provider for the distribution, storage and logistics of XPhyto’s diagnostic products in Germany. According to the update, the agreement secures XPhyto a full-service distribution partner for its 25-minute SARS-CoV-2 (COVID-19) RT-PCR test system (“Covid-ID Lab”). “With this agreement, we have secured a strong partner with an established medical distribution network throughout Germany. This is an exciting and critical step towards commercial sales of Covid-ID Lab,” said Hugh Rogers, CEO and director of XPhyto. “The company’s commercialization strategy is focused on the German market for initial product launch and the creation of robust and sustainable sales.”

To view the full press release, visit https://ibn.fm/nn1ct

About XPhyto Therapeutics Corp.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Researchers Find Possible Explanation Why Some Cancer Drugs Fail

April 21, 2021 13:43:18

A study done by researchers from the McGovern Medical School and the UTHealth School of Biomedical Informatics has found a likely reason why some cancer treatments that eliminate cancerous cells in mouse research models aren’t as effective during human trials. The study was reported in the Nature Communications journal.

For the study, the researchers reported the broad existence of mouse virus cells seen in xenografts that were derived from patients. These patient-derived xenograft (“PDX”) models were created by implanting tumor tissues from humans in mice that are immune…

NOTE TO INVESTORS: The latest news and updates relating to Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Featured in Bell2Bell Podcast

April 21, 2021 13:07:21

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in The Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. Predictive Oncology’s newly appointed CEO, Mel Engle, its CFO, Bob Myers, and CTO of its Helomics subsidiary, Mark Collins, joined the latest episode to discuss updates on POAI’s financial footing, current operations and goals for 2021. “We are in a great situation, probably the best situation that we’ve been in since the existence of the company in terms of our cash capability and the strength of our balance sheet,” Myers said. “We have absolutely no liabilities other than your normal accounts payable, which are quite low. We have a lot of things going on in terms of the income that we expect to get this year and the projects that we have. I think that we are going into these projects in a strong position.”

To view the full press release, visit https://ibn.fm/D2urk

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins, and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Announces Partnership to Offer Virtual Care for Patients with Diabetes

April 21, 2021 09:30:15

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, is partnering with MediOrbis, a telehealth provider specializing in chronic conditions, to provide remote patient monitoring services to Medicare patients with diabetes. The new virtual care initiative means that Medicare patients who have diabetes and who are eligible can receive convenient virtual care that is covered under their existing Medicare benefits. The telehealth services are delivered by MediOrbis with remote patient monitoring through DarioHealth’s AI-powered digital chronic care platform. The announcement noted that the new virtual care program will be available to Dario’s approximately 75,000 members with diabetes. Because an estimated 30% of those members are over age 65, the benefit to these members could be significant, enabling them to benefit from this high-quality, convenient care at lower out-of-pocket costs. The program will also be offered to qualified Medicare members who aren’t using Dario’s offering. “We are excited to partner with MediOrbis to launch this virtual care service for qualified Medicare beneficiaries,” said DarioHealth president and North America general manager Rick Anderson in the press release. “Offering our existing users this program provides users with enhanced services and support at a lower cost. Increasing our offerings to existing customers across all of our market segments is part of our strategy to improve value to our users while increasing revenue per member and lowering our average member acquisition cost. We are excited to partner with MediOrbis and support the expansion beyond Dario’s existing user base to the broader Medicare population, which we believe has the potential to be a multimillion dollar remote patient monitoring opportunity for Dario.”

To view the full press release, visit https://ibn.fm/YiSms

About DarioHealth Corp.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

United Medical Equipment Business Solutions Network Inc. Continues Commitment to Public Health

April 21, 2021 09:25:05

Company remains committed to helping maintain safety and health during global pandemic
Rapid testing identifies virus in the person, provides another layer of protection to the community
UME kits help identify the virus quickly allowing companies and individuals to act quickly to isolate infected individuals

United Medical Equipment Business Solutions Network distributes rapid antigen tests and comprehensive telehealth solutions that allow providers to work more proficiently, health-care systems to work smarter and patients to live healthier lives. Through the provision of COVID-19 rapid kit testing, UME is helping to maintain safety and health during a global pandemic.

Rapid antigen testing provides critical answers and insight to health-care and essential workers as they continue to come into contact with potential cases daily, monitoring their day-to-day health becomes crucial. Symptoms present differently with some…

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in CEO Roadshow Webinar Series

April 21, 2021 09:10:16

Genprex (NASDAQ: GNPX) CEO Rodney Varner will be a regular featured guest in an upcoming webinar series with CEO Roadshow. The series creates a weekly opportunity for Varner to provide weekly updates and highlight GNPX’s gene therapy pipeline in cancer and diabetes; in addition, Varner will answer questions following each week’s presentation. The webinar series is slated to run from April 22 through June 10, 2021, and will begin at 11 a.m. EDT; each presentation is scheduled to last 30 minutes. The company also noted that a recorded version of each webinar would be available on the company website as well on the CEO Roadshow website. Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. The CEO Roadshow webinar series highlights small and mid-cap stocks with potential developments or plans that provide particular interest to those looking for long-term investment opportunities.

To view the webinar presentations, visit https://ibn.fm/MYMh9

To view the full press release, visit https://ibn.fm/eyRxk

About Genprex Inc.

Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, REQORSA (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted fast track designation for REQORSA for NSCLC (“NSCLC”) in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR (“EFGR”) mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the company’s website at www.Genprex.com

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Expands Medical Board with Appointment of Triple-Certified Cardiologist

April 20, 2021 13:44:38

Healthy Extracts (OTCQB: HYEX), a leading developer and manufacturer of science-forward, clinically proven, plant-based and proprietary products for heart and brain health through its subsidiaries, BergametNA(TM) and Ultimate Brain Nutrients(TM), today announced that Dr. Joel Kahn, M.D., a world-renowned, triple board-certified cardiology specialist, has joined Healthy Extracts. According to the update, Dr. Kahn has utilized BergametNA Citrus Bergamot SuperFruit(TM) with thousands of patients and has seen positive cardiovascular benefits and arterial age reversal and flexibility. “We are so excited to welcome Dr. Joel Kahn, one of the few triple-certified cardiologists in the entire U.S., to our Medical Board,” said Duke Pitts, director, president and CEO of Healthy Extracts. “Dr. Kahn’s agreement to join our Medical Board, based on CIMT results of our heart health products, is truly an exciting development. His addition rounds out our incredibly talented and specialized group of doctors and athletes who are committed to the company’s ‘Live Life Young Again’ philosophy. Dr. Kahn will be instrumental in expanding our doctor-to-doctor and consumer sales.”

To view the full press release, visit https://ibn.fm/aldfI

About Healthy Extracts Inc.

Healthy Extracts serves as a platform for developing and acquiring complementary companies that feature science-forward, clinically proven, plant-based and proprietary products in select high-margin and high-growth categories within the multibillion-dollar nutraceuticals market – the first two multimillion-dollar examples of which have already been launched. Company subsidiaries BergametNA(TM) and Ultimate Brain Nutrients(TM) (“UBN”) are providers of nutraceutical natural heart and brain health supplements, including the only heart health supplement containing Citrus Bergamot SuperFruit(TM), the highest quality and concentration of polyphenols and flavonoids available anywhere in the world and exclusive to BergametNA in North America and backed by 17 clinical studies. UBN’s KETONOMICS(R) proprietary formulations improve brain health, including memory, cognition, focus and neuro-energy, and have multiple intellectual property license opportunities for monetizing the company’s portfolio. UBN has six unique formulation patents – two issued and four pending. For more information visit: www.HealthyExtractsInc.com, www.BergametNA.com or www.Fuel4Thought.com.

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Receives License of Year Award for Advances Made with Gene Therapy Program in Diabetes

April 20, 2021 13:11:05

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, was named the recipient of the first-ever License of the Year award presented from the University of Pittsburgh Innovation Institute (“UPII”). The award honors advances made with GNPX’s license from University of Pittsburgh toward progressing the development of its gene therapy for diabetes. GNPX has been involved in groundbreaking, potentially curative gene therapy shown to transform alpha cells in the pancreas into functional beta-like cells. The therapy, which involves the diabetes gene therapy candidate GPX-002, is potentially applicable to both type 1 and type 2 diabetes. Genprex signed an exclusive license agreement with the University of Pittsburgh in February 2020. The agreement involves an innovative gene therapy technology developed by lead researcher, George Gittes, MD at the Rangos Research Center at the University of Pittsburgh Medical Center (“UPMC”) Children’s Hospital. “We thank the UPII for acknowledging the breakthrough work of Dr. George Gittes and his team at the Rangos Research Center at UPMC Children’s Hospital of Pittsburgh, whose efforts have produced this highly innovative therapeutic approach to treating diabetes that could replace the need for insulin replacement therapy and ultimately lead to a cure of this devastating illness afflicting tens of millions of people around the world,” said Genprex president and CEO Rodney Varner in the press release. “We are honored to receive this recognition, considering the great number of cutting-edge technologies coming out of this distinguished university and research center. We thank UPII for bestowing this honor on our gene therapy license with Dr. Gittes and the Rangos Research Center and applaud them for the groundbreaking gene therapy research being conducted at this esteemed institution.”

To view the full press release, visit https://ibn.fm/0AmSi

About Genprex Inc.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Researchers Find That Childhood Exercise, Proper Diet Creates Healthier Adults

April 20, 2021 11:11:04

A new study conducted by researchers from the University of California-Riverside has found that a healthy diet and exercise in childhood creates adults with lower anxiety levels and bigger brains.

This research, which used mice, was the first to investigate the combined long-lasting effects of a healthy diet and exercise when experienced in childhood. The study was reported…

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment Business Solutions Network Inc. are available in the company’s newsroom at https://ibn.fm/UnitedMed

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Appointment of New Global Positions

April 20, 2021 08:54:25

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has appointed two new positions at XP Diagnostics GmbH, its wholly owned German subsidiary. Wolfgang Probst will serve as the company’s new chief operations officer and Manfred Buchberger will be the new head of corporate development. An experienced management and finance consultant with impressive exposure to mergers and acquisitions, corporate re-organizations, and divestitures, Probst has a proven track record of leadership, strategic planning and organizational restructuring. In his new position, he will be responsible for managing the company’s global operations; he will also remain a director of XPhyto and the managing director of XP Diagnostics. A global leader in the medical diagnostics industry, Buchberger is the former CEO and a member of the Global Management Board of a major European medical diagnostics and analytics company. He brings decades of diagnostics industry experience with an expertise in international business development, sales, marketing, and product management. In addition, the company also noted that the two newly appointed executives will oversee the global product launch of and business development for Covid-ID Lab, the company’s rapid 25-minute, point-of-care PCR test for COVID-19.

To view the full press release, visit https://ibn.fm/TocNS

About XPhyto Therapeutics Corp.

XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral-health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. XPhyto has research and development operations in North America and Europe, with an operational focus in Germany, and the company is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit www.XPhyto.com

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Collects 2b Disease Trial Data; Receives NASDAQ Notice Regarding Annual Report

April 20, 2021 08:39:29

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced collection of all patient data for its phase 2b Dupuytren’s disease trial, which was sponsored by the University of Oxford. The double-blind placebo-controlled trial involved 181 patients who were randomized across three sites, two in the United Kingdom and one in the Netherlands. While follow-up on the trial has been delayed by the COVID-19 pandemic, the company is now analyzing the information and has plans to announce top-line data in an upcoming article in a peer-reviewed journal. The company also announced that it has received notification from the Listing Qualifications Department of the Nasdaq Stock Market that it is not in compliance with a Nasdaq Listing Rule requiring filing an annual report for fiscal year 2020. The notification letter has no immediate impact on the listing or trading of ATNF stock on the Nasdaq market. The company noted that it is reviewing the SEC statement; company auditors are also in the process auditing ATNF financial statements to complete the annual report as soon as practical. Regarding the phase 2b disease trial data, 180 Life Sciences CEO stated the following: “Despite the challenges posed by the COVID-19 pandemic and shut down of clinical sites across Europe due to government restrictions, we are fortunate to have had our investigators with the help of additional support from the Wellcome Trust, complete the collection of data. The data is being reviewed and validated, which is not an easy task under current conditions. The analysis will be according to the previously agreed Statistical Analysis Plan. We remain on track to announce a top-line data read out from this trial in Q4 2021.”

To view the full press releases , visit https://ibn.fm/bNbkX and https://ibn.fm/Pa1vN

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease — inflammation. The company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. 180 Life Sciences’s primary platform is a novel program to treat fibrosis using anti-TNF (“TNF”) (tumor necrosis factor), with its lead program in phase 2b/3 clinical trials. For more information about the company, visit www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://ibn.fm/ATNF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Dynamic Global Events’ BioPharma BD&L Summit Accelerates Alliances, Licensing and Partnerships

April 20, 2021 08:29:05

The two-day virtual event to be held from April 22-23 is focused on driving collaborative partnerships to enhance the drug development ecosystem through the art of deal-making
The summit is designed to provide insight into M&A, an attractive option for MedTech and pharmaceutical companies experiencing complex R&D, patent expirations and other impediments to growth
20+ knowledgeable, esteemed speakers will grace the stage

Companies view mergers and acquisitions (“M&A”) as opportunities to broaden their portfolio, expand to international markets and increase leverage and scale. In the MedTech industry, in particular, companies look at M&A as an opportunity to drive positive financial growth and enhance therapeutic solutions (https://ibn.fm/yqmb6), as well as to address industry changes such as those brought by newly introduced regulations, slowed health care spending, negative pricing trends or, more recently, the pandemic.

While the importance of M&A cannot be understated, ultimate success can only be realized if the entire process is flawless from beginning to end. Thus, sharp focus is required when searching for and evaluating potential targets for M&A and…

To receive a discount on your registration, use code IBN2021.

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – GT Biopharma (NASDAQ: GTBP) Releases Q4, Year-End Results, Company Update

April 19, 2021 14:18:32

GT Biopharma (NASDAQ: GTBP), a clinical-stage immuno-oncology company focused on developing innovative therapeutics based on the company’s proprietary natural killer (“NK”) cell engager, TriKE(TM) protein biologic technology platform, has released fourth-quarter and year-end financial and company results for the period ended Dec. 31, 2020. Company highlights noted in the announcement included entering into a GMP manufacturing partnership with Cytovance; the initiation of manufacturing of additional solid tumor TriKE for lung, breast, ovarian and gastrointestinal cancer programs in preparation for FDA clinical trials; and enhancing and expanding the company’s board of directors. In addition, the company completed a successful listing on NASDAQ and closed on a $28.7 million public offering, which resulted in GT Biopharma having more than $30 million in the bank. “2020 was a year of robust clinical progress and milestone achievements for GT Biopharma, which allowed us to accomplish a major corporate milestone in listing GT Biopharma on NASDAQ at the beginning of 2021,” said GT Biopharma chair and CEO Anthony J. Cataldo in the press release. “The emerging data from our GTB-3550 TriKE program in hematological malignancies, MDS and AML, are encouraging in both safety and efficacy profiles. The ongoing data profile has demonstrated significant differences from all other NK cell therapies and NK engager companies, making TriKE a monotherapy, off-the-shelf platform therapeutic. TriKE exerts its therapeutic effect without the need for outside assistance in the form of combination therapies or the addition of supplemental progenitor-derived or autologous/allogenic NK cells. As a result, TriKE therapy cost to patients will be far superior, significantly more economic than progenitor-derived or autologous/allogenic NK cell therapy companies’ offerings. Additionally, the results generated from the GTB-3550 TriKE clinical trial reinforces its versatility, providing a clear rationale to proceed with additional programs in solid tumor and hematologic cancers.”

To view the full press release, visit https://ibn.fm/NwRVk

About GT Biopharma Inc.

GT Biopharma is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary TriKE NK cell engager platform. The company’s TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells (NK cells). GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. For more information, please visit www.GTBiopharma.com.

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Announces FY2020 Business, Financial Results

April 19, 2021 12:03:02

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has released its 2020 financial results and has filed its annual report for the fiscal year ended Dec. 31, 2020. Company highlights include bringing the production of NeuroCaps(TM) to the United States; launching the commercial roll-out of its NeuroEEG(TM) and NeuroCap(TM) on a limited basis in the United States market; establishing wholly owned subsidiaries in Russia and Poland; and a significant increase in research and development efforts. Furthermore, the company announced that it has filed a provisional patent application for a new long-term monitoring EEG cap; in addition, its proprietary NeuroCap is now available in the U.S. pediatric market. Financial highlights include reported revenue of $544,275 for fiscal year 2020, compared to $489,202 for fiscal year 2019 with total company assets at the end of 2020 reaching $440,218 compared to $291,002 at the end of 2019. “In 2020, Brain Scientific made good progress toward our vision of introducing transformative brain diagnostic solutions that apply cutting-edge technologies and establish a new innovative norm for clinicians,” said Brain Scientific board chair Boris Goldstein in the press release. “We made strides on the operations front to improve lead times and quality control, as well as connections to expand our customer base in early 2021.”

To view the full press release, visit https://ibn.fm/tE0gj

About Brain Scientific Inc.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Predictive Oncology’s (NASDAQ: POAI) Subsidiary Refining, Strengthening Personalized Oncology Approach to Ovarian Cancer

April 19, 2021 11:08:13

Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of female reproductive system
TumorGenesis can provide pharmaceutical companies newfound ability for more effective, expeditious drug development
Company is global developer of world-class, innovative technologies using 3D cell culture, media

In the treatment of cancer, most patients receive standard one-size-fits-all drug treatments identified from studying the cancers, treatments and results of other patients. In the evolving world of personalized oncology, the approach entails testing a variety of potential drugs on a patient’s unique tumor to discover which drug, or combination of drugs, might work best. That is precisely the approach that Predictive Oncology (NASDAQ: POAI), through its subsidiary TumorGenesis, takes in addressing ovarian cancer.

According to the American Cancer Society, ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system (https://ibn.fm/D1TkL). The ACS estimated that in…

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Healthy Extracts Inc. (HYEX) Reinforces its Foothold in the Broader Wellness Industry

April 19, 2021 11:05:31

Plant-based supplements gaining popularity for treating chronic cardiovascular and neuro ailments
Healthy Extracts, Inc. intensifies its foothold through its subsidiaries BergaMet North America and Ultimate Brain Nutrients
The company recently announced positive results of clinical studies for two leading products, BergaMet North America’s HERHEART(TM) and UBN’s Fuel4Thought(TM) Brain Booster

Plant-based diets (“PBD”) decrease the serum levels of inflammation by reducing levels of ROS (https://ibn.fm/tA2MU). Also, chronic neuropathic pain is a common debilitating problem and its treatment presents a major challenge to health care. Studies indicate that plants and some constituents of herbal medicine have the potential to cure neuropathic pain (https://ibn.fm/YjtYW).

Healthy Extracts (OTCQB: HYEX) is a leading researcher and manufacturer of plant-based formulations offering healthy supplements that are beneficial for heart and nerve health. The company continues to strengthen its…

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

New Discovery May Redeem Cancer Immunotherapies That Failed During Clinical Trials

April 19, 2021 10:16:58

A new study conducted by researchers from the University of Virginia Cancer Center may be the key to better immunotherapies for the treatment of solid tumors caused by triple-negative breast cancer, colon cancer and ovarian cancer; these cancers were found to be effective in lab tests but failed in human clinical trials.

In the study, the researchers explained how antibody approaches were effective in killing cancer tumors when lab tests were conducted…

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – RYAH Group Inc.’s Products Facilitate Personalized Therapies, Remote Patient Monitoring

April 16, 2021 13:43:41

RYAH Group, a company developing proprietary technology supporting a data-driven approach to health care, has created a range of smart devices set to disrupt the future of medicine. RYAH Group, which is on a mission to advance the world’s transition to remote-health solutions, has done precisely that with its remote health platform called RYAH MD. “RYAH MD is a service that allows clinicians to remotely monitor and control patients’ dosing regimens with RYAH’s dose-measuring products. It provides necessary information that doctors can analyze to learn how different dosing variables affect outcomes. RYAH MD allows the doctor to recommend parameters on the smart devices for dosing, review the information in real-time, and make changes remotely to the doses delivered. It will enable doctors to monitor their patients and ensure that they are following the recommended procedures,” reads an article discussing RYAH’s internet-of-things (“IoT”) suite of products. “RYAH Cloud captures all of the structured and unstructured data from the dosing products and the mobile apps and analyzes the information. This allows doctors and clinics to develop more personalized therapies that can reshape our medical future.”

To view the full article, visit https://ibn.fm/h8siM

RYAH Group Inc.

RYAH Group is a leader in digital health care analytics and technology. By creating a suite of dose-measuring, IoT devices that capture data from seed to consumption, RYAH is positioned to unearth breakthrough discoveries capable of reshaping the understanding of plant-based medicine. For more information, visit the company’s website at www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Offers Innovative Solution in Multibillion and Growing Market

April 16, 2021 12:50:47

Predictive Oncology (NASDAQ: POAI), through its Skyline Medical division, is positioned for opportunity in the fluid management systems and accessories market, which is projected to reach $16.1 billion in 2025 from $8.5 billion in 2020, expanding at a CAGR of 13.6%. These figures are according MarketsandMarkets, which cites several growth factors including technological advancements in fluid management systems (https://ibn.fm/rKWZC). As disposal of waste fluids presents a unique set of challenges for every health care facility, Skyline Medical offers a clear solution. Skyline’s patented and FDA-cleared STREAMWAY System is “the new standard in waste fluid management,” automating the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. “The wall-mount STREAMWAY System ties into a facility’s existing plumbing system,” reads a recent article on the solution and the company’s positioning in the rapidly growing market. “During a surgery or procedure, a single-use filter is snapped into place, a suction tube connected to the unit and proper vacuum level programmed into the display, and the unit takes it from there, calculating the collected amount of fluid while safely disposing of it through the drain system.”

To view the full article, visit https://ibn.fm/qZQHY

About Predictive Oncology Inc.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Real-World Evidence and Market Access Symposium Features Timely Advisement During COVID Era

April 16, 2021 12:37:08

Organized by Dynamic Global Events (“DGE”), a market research and event outreach organization with experience in relevant B2B life science conferences
Taking place April 14-15 with an online, live-streamed format
Experts from some two dozen organizations and companies addressing timely real-world evidence (“RWE”) applicable to the COVID-19 pandemic’s disruptive effect on societies
A potential tool for preparing to transform regulatory submissions, clinical decision making and value demonstrations

Dynamic Global Events (“DGE”) will leverage its extensive market research, targeted outreach and content-driven team’s experience to deliver the latest in a series of relevant B2B events within the life sciences arena, focusing on data analytics during the two-day Real-World Evidence & Market Access Symposium. The symposium will take place April 14 and 15, involving a livestream audience with interests in clinical applications and the lessons derived from using real-world evidence (“RWE”) during the ongoing… For more information, visit the symposium’s web portal at https://dgevents.com/event/real-world-evidence-market-access-symposium/. To receive a discount on your registration, use code IBN2021. Read More>> About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) WP1244 Potentially 500X More Potent than Daunorubicin

April 16, 2021 12:29:36

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company whose lead drug candidate Berubicin has yielded promising results in the treatment of glioblastoma multiforme (“GBM”), has made equally significant strides with its second drug candidate, WP1244. Still currently in development, preclinical work for WP1244 is expected to continue during 2021 and 2022. “WP1244 is a DNA-binding agent believed to be 500-times more potent than daunorubicin in inhibiting tumor cell proliferation,” reads a recent article. “The current target indication for WP1244 includes brain cancers, pancreatic cancers, ovarian cancers and lymphoma. Preclinical studies show high uptake in the brain with antitumor activity.” On the other hand, Berubicin, “a novel anthracycline that is the first anthracycline to cross the blood-brain barrier and is designed to concentrate in tumorous tissue within the brain, is currently entering a potentially pivotal Phase 2 study for GBM.”

To view the full article, visit https://ibn.fm/31RYO

About CNS Pharmaceuticals Inc.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Eyes Q2 Expansion of Growing Portfolio

April 16, 2021 12:11:05

Healthy Extracts (OTCQB: HYEX) recently released its full-year 2020 report. In addition to achieving a 71% jump in its revenue on the back of a plant-based industry boom, the company announced it was at an advanced stage of clinical testing that would culminate in the release of a new product in Q2 2021. The proprietary Fuel4Thought Brain Booster product will add to Health Extracts’ portfolio, which has increased thanks to acquisitions. An article on the developments reads, “Healthy Extracts acquired BergaMet NA in 2019, engaged in selling and distributing a full line of proprietary formulations derived from the rare Citrus Bergamot Superfruit(TM) (‘bergamot’) native to Southern Italy.” The company also acquired Ultimate Brain Nutrients, which “develops unique, plant-based superior proprietary neuro-brain solutions that enhance the brain’s overall health.”

To view the full article, visit https://ibn.fm/nVWiY

About Healthy Extracts Inc.

Healthy Extracts, through its two subsidiaries, BergaMet NA and Ultimate Brain Nutrients (“UBN”), is engaged in proprietary research and development of natural plant-based formulations, as well as sales and distribution of natural-ingredient cardiovascular and neuro products. For more information about the company, visit www.HealthyExtractsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

New Study Suggests That Where You Live May Influence Reproductive Health

April 16, 2021 10:42:21

A recent study conducted by University of Nottingham researchers suggests that the environment in which men inhabit could impact their reproductive health. The study, which was reported in “Scientific Reports,” examined the impact of geographical location on chemicals discovered in testes of dogs. Some of these chemicals have been found to influence reproductive health.

The study centered on dogs because they are common pets and are usually exposed to the same chemicals used in the house as their owners…

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Researchers Discover Children with Down Syndrome Face Higher Risk of Leukemia

April 15, 2021 14:20:38

A large-scale study conducted by researchers from UC San Francisco and UC Davis Health has found that Down syndrome is a high-risk factor for childhood leukemia. The study, which evaluated the leukemia risk in children suffering from Down syndrome, was reported in the “Journal of Pediatrics.” It found a strong link between acute myeloid leukemia, which is a type of blood cancer, and Down syndrome.

Down syndrome, among the most prevalent genetic conditions in Canada and the United States, affects roughly 6,000 infants born annually in the two countries. That equates to roughly one in every 750 babies…

NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc. at Forefront to Speed Economic Recovery

April 15, 2021 13:24:33

United Medical Equipment (“UME,” “UMEBSNI”) is well-positioned to help speed up economic recovery with its FDA-approved COVID-19 rapid test kits. This comes as governments in different parts of the world have expressed interest in rapid testing, citing health and economic benefits. An article on the matter reads, “New York City is wasting no time to leverage the power of this low-cost, high impact option as the city has announced the launch of its Forward Rapid-Test Program. The program will make low-cost rapid testing available to the broader public to support economic recovery by enabling businesses to more safely re-open. The UK government is also looking at introducing rapid lateral-flow testing to open the parts of the economy that could not open last year, including night clubs and theaters.” United Medical’s rapid test “is designed to detect coronavirus antibodies in the bloodstream of infected individuals within 10 minutes, which helps position the company at the core of the strategy to bring both economy and society back to normal.”

To view the full article, visit https://ibn.fm/1AI3w

About United Medical Equipment Business Solutions Network Inc.

NOTE TO INVESTORS: The latest news and updates relating to UME are available in the company’s newsroom at https://ibn.fm/UnitedMed

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Shareholder Letter Outlines Program Highlights, Provides Business Update

April 15, 2021 11:12:21

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has shared a letter to shareholders from chair, president and CEO James Sapirstein. The letter noted that AZRX is on track to launch its niclosamide programs in the clinic, noting that just this month the company announced the initiation of RESERVOIR, its Phase 2 clinical trial of niclosamide for the treatment of COVID-19-related gastrointestinal infections; the company also established an agreement with PPD Inc. (“PPD”), a leading clinical research organization, to manage the upcoming Phase 1b/2a ICI-AC trial, planned for Q2 2021. Sapirstein also shared that the company is continuing the development of MS1819 as a potential treatment for exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”) and is anticipating to release topline data from its Phase 2 combination therapy trial using MS1819 in combination with pancreatic enzyme replacement therapy (“PERT”), which is the current standard of care. The letter noted that the company continues to believe that MS1819 could replace PERT as the gold standard treatment for EPI in patients with CF and chronic pancreatitis (“CP”). The letter also provided further information about MS1819, the company’s most advanced clinical asset. The letter also provided detailed information about the two niclosamide clinical trials scheduled for 2021 and offered a summary of financial information for Q1 2021. “These are exciting times for AzurRx, and we anticipate several catalysts on the horizon,” said AzurRx BioPharma chair, president and CEO James Sapirstein in the letter. “I look forward to working with my management team and fellow board members to execute a business and clinical strategy that has the potential to transform AzurRx and generate substantial returns for our shareholders. We will continue to pursue our efforts to drive long-term shareholder value by delivering safe and effective GI therapies for patients who need them the most, raising our global visibility and broadening our shareholder base. We look forward to continuing what has been a productive 2021.”

To view the full letter, visit https://ibn.fm/cbezg

About AzurRx BioPharma Inc.

AzurRx BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases. The company has a pipeline of three gut-restricted GI assets. The first is MS1819, a recombinant lipase biologic for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis, with two ongoing phase 2 clinical trials. The other two are clinical-stage therapies using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor: FW-420, for the treatment of grade 1 immune checkpoint inhibitor associated colitis (“ICI-AC”) and diarrhea in oncology patients, and FW-1022, for the treatment of COVID-19 gastrointestinal infections. The company is headquartered in Delray Beach, Florida, with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) ‘Covid-ID Lab’ Combines Speed of Rapid Screening with Accuracy of PCR Diagnostic

April 15, 2021 10:43:19

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, is set to launch a solution for improving detection of the virus responsible for the worldwide pandemic. The company recently announced European regulatory approval of its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system. Known as “Covid-ID Lab,” the system is a commercial in-vitro diagnostic device (CE-IVD) designed to help industry professionals and government agencies screen for the virus. XPhyto’s exclusive German diagnostics partner, 3a-diagnostics GmbH, developed Covid-ID Lab to provide rapid, accurate and portable testing capabilities, granting it marketability as a product with increased convenience and decreased operating costs. “Our test is one of the fastest PCR-based COVID-19 tests currently approved. With a sample collection to result time of 25 minutes, Covid-ID Lab combines the speed of a rapid screening test with the accuracy of a PCR diagnostic,” said XPhyto CEO and Director Hugh Rogers of the innovative solution. “Covid-ID Lab is designed for point-of-care testing, particularly in satellite and small-scale labs, such as transportation hubs, borders, care facilities, schools, pharmacies, and hospitality settings.”

To view the full article, visit https://ibn.fm/zVfe8

About XPhyto Therapeutics Corp.

XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about the company, visit www.XPhyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Delivering Readily-Available Solution Amid Growing Need

April 15, 2021 10:24:13

Brain Scientific (OTCQB: BRSF), focused on modernizing the brain diagnostic market through cutting-edge technologies, is fulfilling a growing need for improved neurological monitoring that is cost efficient, disposable and portable. When combating a highly contagious disease, disposable technology helps to ensure that the virus is not spread through equipment. Brain Scientific’s disposable EEG caps are designed for single use and also assist in shortening person-to-person contact due to ease of placement, decreasing transmission between staff and patient. “As health-care facilities and frontline workers move quickly to address COVID symptoms and provide effective treatment, disposable devices offer a solution to rapidly and safely assess neurological changes in these patients,” stated Brain Scientific co-founder and executive chairman Boris Goldstien in a recent article. “Disposable EEG headsets are a cost-effective, readily-available solution that can be adopted for widespread use in these facilities during the current pandemic and moving forward to help health care workers gain a quick, reliable picture of a patient’s condition and receive treatment insights.”

To view the full article, visit https://ibn.fm/pZwVA

About Brain Scientific Inc.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Targets $400M Slice of Massive Global Endoscopy Market

April 15, 2021 10:13:30

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has hailed its first product, the i/Blue(TM) Imaging System, as a breakthrough technology that will advance the accuracy and efficiency of bladder cancer detection and removal, thus helping it capture some market share. The global endoscopy market is valued at $46 billion, of which Imagin is positioned to target $400 million with its bladder cancer detection product. An article detailing this reads, “The company’s patented ultrasensitive imaging product based on optics and light sensors, has potential early-stage cancer-detection abilities. The company’s first target for treatment is bladder cancer.” According to the article, this product provides several advantages, such as improved visualization during minimally invasive surgery (“MIS”). With the i/Blue Imaging System, “the surgeon can simultaneously view both white and blue light video streams in a single frame and in real-time on the surgical monitor, without having to toggle between the two images.”

To view the full article, visit https://ibn.fm/mhBPd

About Imagin Medical

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Study Finds That Sugar Compromises Brain Development in Children

April 14, 2021 12:43:04

A recent study conducted by a faculty member from the University of Georgia, in partnership with a team of researchers from the University of Southern California, has found that the daily consumption of beverages sweetened with sugar during adolescence damages performance on a memory and learning task during adulthood. The group of researchers demonstrated that changes in the bacteria found in the gut could be the key to the memory impairment caused by sugar.

High-sugar diets have also been associated with health effects such as heart disease and obesity as well as impaired…

NOTE TO INVESTORS: The latest news and updates relating to Predictive Oncology (NASDAQ: POAI) are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Colleague Receives 2021 International Dupuytren Award

April 14, 2021 12:03:42

180 Life Sciences Corp. (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced that Dr. Lynn Williams, PhD, has received the International Dupuytren Award 2021 for Basic Research. Williams’s research is sponsored by 180 Life Sciences. The award was given for research conducted by and a paper written by Williams. The paper, which was published in “Proceedings of the National Academy of Science, USA,” was titled “Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300.” The research identified the collagen VI pathway, which 180 Life Sciences is now pursuing in preclinical studies. The findings reported in the paper were compiled as a result of Williams’s work as a member of Professor Jagdeep Nanchahal’s research team; Nanchahal is chairman of 180 Life Sciences’ Clinical Advisory Board. The announcement noted that Dr. Thomas Layton, another member of Nanchahal’s research team in Oxford, was named as a joint recipient of the International Dupuytren Award in both 2020 and 2019. Nanchahal and his clinical research team received the 2019 award for the publication of the phase 2a clinical trial data. “This pivotal research for which Dr. Williams has received this award, was published in a high-impact journal and provides insight into Collagen VI pathways to identify novel potential therapeutic targets for fibrotic diseases,” said 180 Life Sciences CEO James Woody in the press release. “This research from our team, led by Professor Jagdeep Nanchahal, is the foundation of our program to develop new treatments for fibrosis.”

To view the full press release, visit https://ibn.fm/1LF2E

About 180 Life Sciences Corp.

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Appoints Widely Acclaimed Leader as New Medical Director of Clinical Education

April 14, 2021 11:51:46

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), today announced the appointment of Mimi Guarneri, MD, FACC as an independent consultant serving in the role of medical director of Clinical Education, effective April 1, 2021. Dr. Guarneri is widely acclaimed as a leading Integrative cardiologist in America and is board-certified in cardiovascular disease, nuclear cardiology and internal and integrative holistic medicine. “We are very excited to welcome Dr. Guarneri to Vivos Therapeutics in this new capacity,” said Kirk Huntsman, Vivos’ chairman and chief executive officer. “As a global medical leader in comprehensive and holistic approaches to cardiovascular disease and sleep disorders, she will be a valuable addition to our growing organization. Her wealth of experience and credibility as an award-winning physician and researcher will help inform other physicians about our breakthrough diagnostic and treatment technologies.”

To view the full press release, visit https://ibn.fm/JYD5M

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative treatments for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos believes that its Vivos System technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos oral appliances have proven effective in over 15,000 patients treated worldwide by more than 1,200 trained dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and can eliminate or significantly reduce symptoms and conditions associated with mild-to-moderate OSA. The Vivos System has been shown to significantly lower Apnea Hypopnea Index scores and improve other conditions associated with OSA. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using the Vivos System. For more information, visit www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) to Host Private Seminar to Present MiQLab Data from Recent Study

April 14, 2021 10:29:31

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, announced that it will host a private event featuring Dr. Shelley Rankin, a professor of microbiology at the University of Pennsylvania’s School of Veterinary Medicine (Penn Vet). Attended by a select group of veterinarians, the private seminar will feature data compiled by Rankin based on her studies evaluating the use of LexaGene’s MiQLab to detect Staphylococcus in specimens gathered from canine skin infections. The event will also include information regarding the use of molecular diagnostics in veterinary medicine as well as analytical and clinical data generated using LexaGene’s MiQLab system. The studies performed by Rankin and LexaGene were designed to analyze and evaluate the performance of LexaGene’s MiQLab to detect common bacterial pathogens encountered in veterinary medicine. To conduct the analytical studies and clinical urine study, MiQLabs were equipped with LexaGene’s MiQLab(TM) Bacterial and AMR Test. The test is designed to screen for 7 common bacterial pathogens and 13 different antimicrobial resistance factors. Rankin noted that LexaGene’s MiQLab returns a molecular analysis on specimens in a fraction of the time it takes for culture to return results, enabling veterinarians to quickly identify infection and offer pet owners evidence-based treatment options. “Our goal has always been to have the MiQLab generate high-quality data inside veterinary clinics where veterinarians can use this data to guide treatment decisions,” said LexaGene CEO and founder Jack Regan in the press release. “These data prove we have achieved this goal. Our sales team will be using these data to secure sales in the veterinary market, which has relatively few options for quality in-hospital pathogen testing.”

To view the full press release, visit https://ibn.fm/4JOmQ

About LexaGene Holdings Inc.

LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for onsite rapid testing in veterinary diagnostics and food safety, and for use in open-access markets such as clinical research, agricultural testing and biodefense. End users simply need to collect a sample, load the sample onto the instrument with a sample preparation cartridge, enter the sample ID and press go. The MiQLab system delivers excellent sensitivity, specificity and breadth of detection, and can return results in approximately one hour. The unique open-access feature is designed for custom testing so that end users can load their own real-time PCR assays onto the instrument to target any genetic target of interest. For more information about the company, visit www.LexaGene.com.

NOTE TO INVESTORS: The latest news and updates relating to LXXGF are available in the company’s newsroom at https://ibn.fm/LXXGF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Enters Agreement for Upcoming Phase 1b/2a Clinical Trial

April 13, 2021

April 13, 2021 13:46:01

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has entered into an agreement with PPD Inc. (NASDAQ: PPD) for its upcoming phase 1b/2a clinical trial. PPD, a leading global contract research organization will manage the clinical trial using both oral immediate-release tablet and topical rectal enema foam formulations of micronized oral niclosamide, or FW-420 (“CRO”). The trial is designed to evaluate proprietary formulations of micronized niclosamide for grade 1 colitis and diarrhea in oncology patients receiving treatment with immune checkpoint inhibitors (“ICIs”). This is the second clinical trial involving niclosamide that the CRO will manage for AzurRx. As previously announced, PPD is also managing AzurRx’s phase 2 clinical trial to investigate niclosamide as a treatment for COVID-19-related gastrointestinal infections; that trial is planned for Q2 2021. “The goal of our FW-420 clinical program is to develop a safe, effective, and non-systemic treatment for immune checkpoint inhibitor-associated colitis, and we are excited to once again partner with PPD to begin the preparations for our Phase 1b/2a clinical trial,” said AzurRx BioPharma president and CEO James Sapirstein in the press release. “The development of immune checkpoint inhibitors has marked a major advance in cancer therapeutics, but the drugs can induce a serious inflammation of the bowels, which if left unchecked, can prove life-threatening and force patients to halt treatment. There are currently no treatments available for grade 1 colitis resulting from the use of ICIs. We believe an oral, non-absorbed treatment, such as FW-420, could prevent the condition from progressing and enable patients to continue their treatment regimen uninterrupted. We hope to rapidly advance the FW-420 program with the support of PPD.” To view the full press release, visit https://ibn.fm/k4JfZ About AzurRx BioPharma Inc. AzurRx BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases. The company has a pipeline of three gut-restricted GI assets. The first is MS1819, a recombinant lipase biologic for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis, with two ongoing phase 2 clinical trials. The other two are clinical-stage therapies using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor: FW-420, for the treatment of grade 1 immune checkpoint inhibitor associated colitis (“ICI-AC”) and diarrhea in oncology patients, and FW-1022, for the treatment of COVID-19 gastrointestinal infections. The company is headquartered in Delray Beach, Florida, with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com. NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX About BioMedWire BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork

Researchers Find New Way to Categorize COVID-19 Patients

April 13, 2021

April 13, 2021 13:16:41

A new study conducted by researchers from the University of Minnesota Medical School and their colleagues has found three phenotypes of the novel coronavirus, which demonstrate distinct characteristics as well as different clinical outcomes, complications and comorbidities in patient populations. The three COVID-19 phenotypes were discussed in detail in the researchers’ study, which was reported in the open-access “PLOS ONE” journal.

The coronavirus has infected more than 18 million individuals as well as led to the death of more than 700,000 people across the globe. The disease’s presentation varies considerably, which suggests that not only do distinct clinical phenotypes exist, but those phenotypes may also respond…

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Nonhospitalized Long-Haul Coronavirus Patients Susceptible to Cognitive Dysfunction

April 12, 2021 14:03:14

A group of researchers from the Feinberg School of Medicine at Northwestern University has discovered additional evidence of cognitive dysfunction in many coronavirus patients who were not hospitalized after contracting the infection. The group’s findings were reported in the “Annals of Clinical and Translational Neurology” journal.

In the study, the researchers looked into medical data of nonhospitalized coronavirus patients from 21 different states who were experiencing long-term symptoms…

NOTE TO INVESTORS: The latest news and updates relating to AzurRx BioPharma Inc. (NASDAQ: AZRX) are available in the company’s newsroom at https://ibn.fm/AZRX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – InvestorBrandNetwork and BioMedWire Collaborate to Deliver Incredible Visibility and Reach for DGE’s Upcoming 2021 Events

April 12, 2021 13:52:39

InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting companies to the investment community through 50+ brands, today announced that it will partner with Dynamic Global Events (“DGE”) as an official media partner for upcoming events in 2021. In addition, BioMedWire (“BMW”), a specialized communications platform for the life sciences sector and one of the 50+ brands of the InvestorBrandNetwork, will also serve as an official media partner for DGE’s upcoming events. InvestorBrandNetwork and BioMedWire will provide dedicated virtual coverage, including a syndicated article on each event with full dissemination to IBN’s 5000+ strategic syndication partners, social media coverage of the events through IBN’s accounts that have collectively amassed more than 2 million likes and followers across a variety of platforms, as well as featured placement on IBN and BMW event pages. “We are delighted to be collaborating with InvestorBrandNetwork and BioMedWire,” said DGE’s Marketing Manager, Elizabeth Stanislaw, MBA. “IBN’s widespread syndication network and dozens of trusted brands will deliver incredible visibility for our sponsors. Moreover, their multifaceted approach will complement our existing strategy to reach larger audiences.”

To view the full press release, visit https://ibn.fm/I08Ja

About Dynamic Global Events (“DGE”)

DGE has established itself as a leader within the life sciences industry by providing business-to-business (“B2B”) events that service the dynamic informational and networking needs of the pharmaceutical, biotechnology, medical device, health care, and allied industries. Founded in 2017, DGE has rapidly made a strong impression with its diverse portfolio of live, virtual and hybrid events spanning a wide range of topics, including: Advancing Women’s Leadership (“AWLC”), Virtual Clinical Trials (“VCT”), Digital Marketing for Life Sciences, Medical Affairs Leadership (“MALF”) and Business Development & Licensing (“BD&L”). For more information about Dynamic Global Events, visit www.DGEvents.com.

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Files First Order for Rapid COVID Test Kits Amid European Regulatory Approval

April 12, 2021 12:06:47

Bioscience technology accelerator XPhyto Therapeutics Corp. recently announced it had placed its first order for its Covid-ID Lab rapid, portable virus test from its German development partner
XPhyto received approval for the test kit last month from European regulators with oversight of in vitro diagnostic device (CE-IVD) use certification and the internationally agreed-on ISO 13485 medical product quality standards
The Covid-ID Lab is designed to help beleaguered industries and government regulators quickly screen for the COVID-19 virus at point-of-care sites, and the company expects to begin sales and distribution in April
XPhyto has just completed a rebranding effort that includes the launch of a new website
The company expects to begin launching other bacteria and virus diagnostic products later this year

With confidence in the world’s mounting recovery from the COVID-19 pandemic growing this year, bioscience industry holding company XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is stepping up its efforts to produce and ultimately commercialize next-generation diagnostic products and new active pharmaceutical ingredients, particularly in regard to the pandemic response.

XPhyto has placed its first order for the company’s Covid-ID Lab product from its exclusive diagnostic development partner, Germany’s 3a-diagnostics GmbH, as announced in a…

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Brain Scientific Inc. (BRSF) Changing the Landscape by Tackling Neurology Deserts

April 12, 2021 11:42:29

Distribution of neurologists across the U.S. is uneven with 20 states experiencing neurology deserts
Brain Scientific has developed tools that help providers in neurology deserts provide access to neurological care
With explosion of telemedicine services and increased integration of advanced practice providers, neurologists’ shortage may improve

Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company, is directly tackling the shortage of neurologists in the United States with cutting-edge technologies. By creating cost-efficient, disposable and portable EEGs, BRSF makes neurology care more accessible without putting excess strain on the already overextended neurologist labor pool.

Between 2001 and 2016, the American Academy of Neurology (“AAN”) reported that out-of-pocket costs shot up substantially for privately insured patients. In addition, the distribution of neurologists across the U.S. is uneven, with patients in rural areas less likely to…

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Presentation of Positive REQORSA(TM) Preclinical Data to Audience of World’s Leading Cancer Researchers

April 12, 2021 11:17:46

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its collaborators presented positive preclinical data for TUSC2 immunogene therapy (REQORSA(TM)) in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (“NSCLC”). According to the update, collaborators also presented positive preclinical data for the use of REQORSA in combination with targeted therapies for the treatment of NSCLC. The data were presented at the 2021 American Association of Cancer Research (“AACR”) annual meeting. “We are pleased to have these positive data that provide further support for the therapeutic potential of REQORSA in combination with immunotherapies and targeted therapies in NSCLC presented before an audience of the world’s leading cancer researchers. These data are particularly encouraging as we look to initiate our upcoming combination Acclaim-1 and Acclaim-2 clinical trials of REQORSA in NSCLC,” said Rodney Varner, president and chief executive officer of Genprex. “We know that many patients inevitably develop resistance to immune checkpoint blockade therapy or EGFR-TKI therapy. These data show that REQORSA in combination with immunotherapies and targeted therapies may provide enhanced efficacy in NSCLC that has become resistant to these regimens, offering hope to a large patient population who currently has limited treatment options.”

To view the full press release, visit https://ibn.fm/xMOps

About Genprex Inc.

Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, “REQORSA(TM)” (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, visit the company’s web site at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Research Discovers Vaccinating Women Against COVID-19 Passes Antibodies to Unborn Babies

April 9, 2021

April 9, 2021 13:41:32

Researchers from Harvard, MIT, the Ragon Institute of MGH, Brigham and Women’s Hospital and Massachusetts General Hospital recently conducted a study that discovered that the new mRNA coronavirus vaccines were highly efficacious in producing antibodies against the SARS-CoV-2 virus in lactating and pregnant women. The researchers also showed that the vaccines offered protective immunity to newborns through the placenta and breast milk.

Their findings were reported in the “American Journal of Obstetrics and Gynecology” and observed 131 women, 16 of whom weren’t pregnant, 31 who were lactating and 84 who were pregnant, all of reproductive age. All the study participants received one of the two new mRNA vaccines: Moderna or Pfizer/BioNTech. The antibodies were found to be equal in all three groups. Additionally, any side effects observed after the vaccines…

NOTE TO INVESTORS: The latest news and updates relating to Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

RYAH Group Inc. Offers IoT Suite of Products Disrupting Future of Medicine

April 9, 2021

April 9, 2021 13:30:30

Every product features three parts: dosing device, formulation accessory and mobile app
HIPPA-compliant cloud collects data along each step that is essential in tailoring personalized treatment plan
RYAH offers multi-product ecosystem that provides remote-health solutions in patient treatment

RYAH Group a digital health-care analytics and technology company, has developed an ecosystem of IoT products in its mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments (https://ibn.fm/1wvz4). Every product features three parts: the device, the formulation accessory (QR labeled product) and the mobile application. These parts work together to control the dosing while also capturing important data that can lead to breakthroughs in plant-based medicine.

Every RYAH dose-measuring product has an innovative dose-control solution. Using QR-labeled products, patients can track what they use and evaluate what dosing parameters work best for each product. The QR labeling allows for advanced session tracking and journaling and is designed to ensure safety. Patients can then control and rate the effectiveness of each session on…

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Eyes Expansion of AI-Driven Clinical Models

April 9, 2021

April 9, 2021 11:22:28

Predictive Oncology (NASDAQ: POAI) has set sights on other cancers after completing its data generation milestones in a collaborative study with UPMC-Magee Women Hospital. With the comprehensive genomic and transcriptomic sequencing of patient samples now complete, thanks to the study, and patient outcome data having been obtained from UPMC-Magee, “these data will now be used to drive POAI’s AI models of ovarian cancer and their internal ovarian cancer drug re-purposing project.” This is according to an article detailing the matter. “‘The successful generation of high-quality genomic and transcriptomic data from archived materials at Helomics, together with the gathering of historical outcome data from our collaborator UPMC-Magee, demonstrates that we can leverage Helomics’ unique asset and deliver significant value,’ said Predictive Oncology CEO Dr. Carl Schwartz. ‘Furthermore, this project is a template we can use to partner with other health care institutions and expand our AI-driven clinical models to other cancers.’”

To view the full article, visit https://ibn.fm/fMpmj

About Predictive Oncology Inc.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Commercialization Team Set to Launch Rapid POC COVID Test Solution

April 8, 2021 13:53:07

Bioscience technology accelerator XPhyto Therapeutics Corp. is working with development partner 3a-diagnostics GmbH to roll out its pandemic-related virus diagnostic tool for the European market planned in April
The test solution, dubbed “Covid-ID Lab,” received European regulatory approval last month
XPhyto’s product is designed to be portable and rapid in its response time to help decrease testing operation costs and increase convenience of use
News reports about the COVID-19 pandemic reflect a growing optimism that vaccine, mask and distancing protocols may be helping to drive down infection rates, although the reports note the virus continues to have a deadly effect on many people
Government and industry leaders have been looking for accurate and rapid diagnostic tools that may make it easier for travel operations and other businesses to resume robust activity despite the continued presence of the infectious virus

Vaccine distribution to millions of people and reports of declining rates of COVID-19 infection are generating optimism in the United States that the health crisis and its economic devastation are beginning to retreat before a modern medical technology assault, even as health officials continue to issue warnings that the deadly virus and its variants are still very active (https://ibn.fm/cl8Vk).

Bioscience technology accelerator XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is now ready to launch its own solution for improving detection of the virus responsible for the worldwide pandemic. The company announced on March 18 that European regulatory officials have approved its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system, known more simply as…

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Researchers Find That Dining Out Frequently Increases Risk of Mortality

April 8, 2021 13:39:20

Researchers from the University of Iowa recently examined the link between the risk of death and dining out and came to the conclusion that eating out too often was linked to an increased risk of all-cause death. The findings were reported in the “Journal of the Academy of Nutrition and Dietetics.”

Eating out is a popular activity globally, and while not much research has been done into its link with health outcomes, the conclusion warrants…

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment Business Solutions Network Inc. are available in the company’s newsroom at https://ibn.fm/UnitedMed

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin to Demonstrate Effectiveness vs. Established Chemotherapy Drug in Phase 2 Trial

April 8, 2021 13:22:14

CNS Pharmaceuticals (NASDAQ: CNSP) continues to aggressively pursue FDA approval for its lead drug candidate, Berubicin. The novel candidate is the first anthracycline that appears to be able to cross the blood-brain barrier to combat tumors — stepping up its cancer-fighting potential. Berubicin was the subject of a Phase 1 safety trial conducted by Reata Pharmaceuticals approximately 15 years ago. One of the trial participants has remained alive and cancer-free as of the most recent evaluation late last year, while two other patients in the small study saw reductions of greater than 25% (one being an 80% reduction) in the size of their tumors. CNS Pharmaceuticals is advancing the development of Berubicin for potential commercialization in treating glioblastoma multiforme (“GBM”), a type of brain cancer that is nearly 100% fatal in one year after diagnosis. The company has progressed its plans for a world-spanning Phase 2 trial comparing Berubicin’s response to the effectiveness of established chemotherapy drug lomustine in 243 GBM patients. “The participants for the Phase 2 study will be adult GBM patients with recurrent disease (Grade IV, as measured by the World Health Organization) after the failure of standard first-line therapy,” reads a recent article on the new trial. “The primary endpoint of the study is to demonstrate overall survival, ‘a rigorous endpoint the FDA recognizes when a statistically significant improvement can be shown relative to a randomized control arm,’ the company states.”

To view the full article, visit https://ibn.fm/AEyIb

About CNS Pharmaceuticals Inc.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Creates Win-Win Solution for Hospitals, Patients

April 8, 2021 12:50:35

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has developed a solution set to lower the cost of treating bladder cancer and also help hospitals save money. As a result, Imagin will create a win-win situation for every party involved. The i/Blue(TM) Imaging System, Imagin’s proprietary solution, achieves this in two ways. “By displaying the blue light image that shows the highlighted cancer cells alongside the white light image that shows the full landscape of the bladder, the i/Blue Imaging System will provide surgeons with improved visualization to locate and resect tumors. The overall result is a reduction in the cost of treatment as detailed in a report by Urology Times.” The article detailing these developments continues, “Further, the i/Blue Imaging System’s camera head can be attached to any cystoscope, meaning that a hospital need not buy new cystoscopes to use the blue light fluorescent technology.”

To view the full article, visit https://ibn.fm/eG3En

About Imagin Medical

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Brain Scientific Inc. (BRSF) Meeting the Needs of Neuro Research

April 8, 2021 12:21:10

BRSF is creating mobile, easy-to-use electroencephalogram (“EEG”) devices that enhance research integrity
There is an increasing desire to understand the brain’s capabilities and harness them for healing
Brain Scientific provides a cost-efficient, pre-gelled, disposable and wireless solution that provides the same signal quality as the traditional wired EEG

A growing consumer market for brain-computer interface (“BCI”) technology has some researchers worried about the quality of the data being collected. Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has developed wireless, portable, easy-to-use electroencephalogram (“EEG”) devices that do not compromise research integrity.

Data collected from consumer-centric, low-cost BCIs are typically not as efficient or as pristine as that retrieved from research-grade conventional wired EEGs. However, the sudden growth of this market, which reached 1.2 billion in 2019, is largely due to a rise in neuroprosthetic conditions, a growing geriatric population, and a desire to communicate and facilitate movement in…

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Patients with Incurable Brain Cancers Find New Hope in University Study, Upcoming CNS Pharmaceuticals (NASDAQ: CNSP) Clinical Trial

April 7, 2021 13:47:22

Glioblastoma Multiforme (often known simply as GBM) is a fatal, incurable class of brain cancers that usually leaves patients only about 15 months to live once they are diagnosed
A recent study by the Washington University School of Medicine found that the length of survivability appeared to improve when the standard chemotherapy regimen was given in the morning instead of the evening
Brain cancer drug developer CNS Pharmaceuticals is also working on a solution to improve the quality of GBM care, seeing hope in its lead drug candidate, Berubicin, which showed promise in a small Phase 1 trial nearly 15 years ago
One patient from that Phase 1 trial was still alive and cancer-free as of the most recent assessment in November
CNS expects to begin a larger, multi-center potentially pivotal trial imminently (as well as collaborating on two Polish trials conducted by sublicensee partner WPD Pharmaceuticals), comparing Berubicin’s performance to the chemotherapy drug lomustine in hundreds of patients at nearly 60 oncology centers around the world

A new study recently completed by the Washington University School of Medicine in St. Louis has found that glioblastoma (“GBM”) brain cancer patients receiving the current chemotherapy standard of care had longer survivability rates if they switched from receiving treatments in the evening to receiving the treatments in the morning — encouraging news for patients with the incurable illness, as well as for neuro-oncology researchers attempting to develop improved treatments, including biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP).

“In my lab, we were studying daily rhythms in astrocytes, a cell type found in the healthy brain. We discovered some cellular events in healthy cells varied with time of day,” professor of biology Erik D. Herzog, PhD, stated in a Science Daily report on the study Herzog co-authored with professor of…

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Shares Promising Clinical Study Results for HERHEART(TM), Fuel4Thought(TM) Brain Booster

April 7, 2021 12:12:44

Healthy Extracts (OTCQB: HYEX) is engaged in proprietary research and development of natural plant-based formulations, sales, and distribution of cardiovascular and neuro products. HYEX recently announced promising clinical study results for two of its subsidiary companies’ leading products: BergaMet North America’s HERHEART(TM) and Ultimate Brain Nutrients’ Fuel4Thought(TM) Brain Booster. “HERHEART(TM) is an exclusive natural supplement that is scientifically formulated specifically for women to support cardiovascular health, including perimenopausal symptoms. The study was conducted in 35 postmenopausal women with sexual dysfunction at the University Magna Graecia of Caranzaro in Italy. Results indicated that patients who were administered HERHEART(TM) reported a 40% decrease in mood swings and 60% reduction in hot flashes, along with a 45% increase in energy and a 40% to 70% increase in desire and arousal. The supplement was also shown to have beneficial effects in fat metabolizing, lower cholesterol levels and anti-inflammatory action,” reads a recent article discussing the products. “Shortly after releasing results for HERHEART(TM), the company’s UBN subsidiary released its study of Fuel4Thought(TM) Brain Booster, showing impressive results in brain activation, sports vision, hand-to-eye coordination, and auditory reaction time. The results were presented by Dr. Neil Wolkadoff and Dr. Gerald Haase at the 2020 meeting of the American College of Sports Medicine. The prospective, randomized, double-blind, and placebo-controlled trial was completed at the Colorado Center for Health and Sport Science.”

To view the full article, visit https://ibn.fm/aIyjX

About Healthy Extracts Inc.

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Researchers Find Evidence Suggesting That Coronavirus Can Cause Type 2 Diabetes

April 7, 2021 11:11:46

A group of scientists from Monash University and King’s College London has developed a database of information that may help researchers find the link between type 2 diabetes and the coronavirus. The group designed the database for the following reasons: first, the increasing evidence that suggests that the coronavirus can actually cause individuals to become diabetic, and second, when compared to the general population, individuals who have type 2 diabetes are more likely to experience serious coronavirus symptoms and to die from the disease. Type 2 diabetes is a chronic condition that impacts the way the body processes blood sugar.

The database, dubbed the COVIDIAB registry, has been created to assist medical researchers to understand the association between diabetes and the coronavirus. The data that was gathered from patients included whether the diagnoses were new onset. The researchers suggest that the amount of data will increase as researchers learn more about the effect of the coronavirus…

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Innovative Imaging Technology Overcoming Challenges Involving Bladder Cancer Visualization

April 7, 2021 11:11:12

90% of the cystoscopies performed on bladder cancer patients use white light, which cannot always detect cancer margins or tumors that lie flat against the bladder wall. The American Urology Association recommends blue light for cystoscopic procedures involving bladder cancer.
Imagin Medical’s i/Blue Imaging System(TM) provides the simultaneous, side-by-side display of white light and blue light images, making it easier to visualize cancer margins and flat tumors, potentially resulting in lower recurrence rates
The company is has transitioned to the manufacturing stage of the i/Blue System with their contract manufacturer, Lighthouse Imaging
Bladder cancer is the sixth most prevalent cancer in the United States, with approximately 81,400 new cases in 2020 and approximately 17,980 deaths in 2020

Surgical imaging company, Imagin Medical (CSE: IME) (OTCQB: IMEXF), is on the innovative edge of visualizing bladder cancer, aiming to overcome the challenges associated with current imaging techniques. The conventional treatment for bladder cancer is white light cystoscopy that allows doctors to insert a cystoscope equipped with a lens through the urethra to illuminate and examine the outer wall of the bladder.

Cystoscopies may be performed for the following…

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Healthy Extracts Inc.’s (HYEX) “Live Life Young Again” Strategy Reflects The Company’s Continued Optimism For 2021

April 6, 2021

April 6, 2021 12:07:34

Healthy Extracts Inc. recently declared its 2020 Q4 results, with revenue growth at 71% over the previous year
The company’s 2021 strategy “Live Life Young Again” aligns with its plant-based product range and its overall confidence for 2021
Results of the clinical studies of the Fuel4Thought Brain Booster product were published in the renowned World Journal of Advanced Research and Reviews

Healthy Extracts (OTCQB: HYEX), is engaged in the research, development, and sale of natural plant-based products that concentrate on nerve and heart health. The company’s growth and expansion are evident in the company’s robust 2020 Q4 results. Their latest financial report highlights the revenue increase of 71% at $1,276,559 compared to 2019 revenues of $748,377. The plant-based food industry is expected to reach a value of $74.2 billion in 2027, guided by a CAGR of 11.9% from 2020 to 2027 (https://ibn.fm/qeyzR).

Duke Pitts, president of Healthy Extracts Inc., stated that the 2020 results reflected the upward momentum of the company. The company recently changed its name from Grey Cloak Tech Inc. to Healthy Extracts, Inc., better aligned with the…

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Researchers Create Lab-Made Heart Valves That Grow with Patient

April 6, 2021

April 6, 2021 11:33:04

A recent study led by researchers from the University of Minnesota, both from the College of Science and Engineering and the Medical School, demonstrated how heart valves that were developed in the lab and infixed in young lambs for a year could grow in the recipient. When tested in the same lamb model, the researchers found that the valves demonstrated decreased calcification and better flow of blood function in comparison with valves derived from animals.

If those results are confirmed in humans, these heart valves may help prevent multiple valve replacement surgeries for children born annually with heart defects. Additionally, these valves can be stored for roughly half a year, which means that they could offer…

NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Initiates Phase 2 RESERVOIR Trial for Treatment of COVID-19 GI Infections

April 6, 2021

April 6, 2021 10:02:44

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced that it has initiated its Phase 2 RESERVOIR clinical trial of a proprietary oral formulation of micronized niclosamide (“FW-1022”) for the treatment of COVID-19-related gastrointestinal (GI) infections. Patient enrollment is expected to begin in April 2021 with topline data anticipated in the first quarter of 2022. “Initiation of the Phase 2 clinical trial of FW-1022 for the treatment of COVID-19 GI infection, or the RESERVOIR trial, is a significant milestone for AzurRx and an important advance in the ongoing battle to help those infected by COVID-19 to overcome the often long-lasting effects of the virus,” said James Sapirstein, chairman, CEO and president of AzurRx BioPharma. “COVID-19 is a pernicious disease and, despite the ongoing vaccine rollout, one that continues to impact hundreds of thousands of people worldwide every day in addition to the millions who have already been infected. For many, the after-effects of COVID-19 can be as bad as the disease itself, and this includes a growing number who experience severe GI complications due to what many believe is the ability of SARS-CoV-2 to hide in reservoirs within the GI tract. We believe micronized oral niclosamide has the potential to target SARS-CoV-2 directly in the gut and, doing so, become an important addition to the armamentarium of therapeutics that will unfortunately be required by many who contract COVID-19.”

To view the full press release, visit https://ibn.fm/kh4lH

About AzurRx BioPharma Inc.

AzurRx BioPharma is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases. The company has a pipeline of three gut-restricted GI assets. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis, currently in two Phase 2 clinical trials. AzurRx is launching two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor; FW-1022 for COVID-19 gastrointestinal infections and FW-420 for grade 1 immune checkpoint inhibitor-associated colitis and diarrhea in oncology patients. The company is headquartered in Delray Beach, Florida, with clinical operations in Hayward, California. For more information, visit www.AzurRx.com.

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Brain Scientific Inc. (BRSF) Provides Affordable Solutions for COVID Studies

April 5, 2021 14:14:35

Researchers struggle to understand the immediate effects of COVID, with no clear census on the long-term neurological impact
COVID-19 has shown itself to be unique in how it interacts with the brain
Brain e-tattoos implanted in forehead will be next wave of innovation for neurology

Brain Scientific (OTCQB: BRSF) is meeting the growing need for improved brain monitoring with cost-efficient, disposable, and portable cutting-edge technology. This last year has seen an increased demand for disposable neurological technology accessible to all, adaptable for widespread use, and that provides quick, reliable information on the patient’s condition.

As the pandemic winds down, thanks to dedicated medical workers, social-distancing, mask-wearing and new vaccines, there are still many questions that need to be…

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Analysts Forecast That Smoking May Become Extinct in a Generation

April 5, 2021 13:42:05

According to analysts from Jefferies, two decades from now, there may be no smokers in the market. Tobacco firms and governments happen to be on the same side in this shift, especially now that more countries are adopting smoke-free targets and companies are advocating for smokers to use alternative products such as oral nicotine and vaping.

In a note, one of the analysts, Owen Bennett, stated that as tobacco ambitions and regulators align, no smokers in a generation may become a reality, adding…

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

United Medical Equipment Showcases Recent Rapid-Testing Research, Committed to Playing Key Role in COVID-19 Screening

April 5, 2021 13:41:58

Rapid testing is cheaper, faster than PCR testing; some fear test sensitivity is too low
Recent studies show that test sensitivity is secondary to frequency and turnaround time for effective COVID-19 screening
UME widespread rapid testing gains momentum as safe, reliable and more cost-effective alternative

As a trusted supplier of testing kits, United Medical Equipment (“UME”) is eager to provide assistance and support in the fight against COVID-19 as as research indicates effectiveness of rapid testing for COVID-19 screening (https://ibn.fm/eZoVI). Governments have invested significant resources in scaling up testing capacity as a response to the pandemic outbreak. Because SARS-CoV-2 can spread from individuals with presymptomatic, symptomatic and asymptomatic infections, the containment of the virus and reopening of societies may… Read More>> NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc. Poised Amid Demand for Rapid Testing Kits

April 5, 2021 12:50:54

United Medical Equipment (“UME,” “UMEBSNI”), a company offering rapid COVID-19 testing kits, looks positioned to benefit from the high demand for its products. The demand arises from expert recommendations that identifying those infected through rapid testing could help curb the virus and prevent the emergence of new variants. An article about these developments reads, “‘Testing is actually more important now than it was eight months ago because of the high contagiousness rate of these new variants,’ Mara Aspinall, a professor of health practice at Arizona State University, said in a recent interview for NPR. ‘It is critical to stop these new strains right in their tracks. And the only way to do that is to test.’ Identifying those infected through country wide rapid testing could be vital for curbing the virus and preventing new variants from emerging. The country reportedly needs tens of millions of tests every day to avoid another surge, while it buys time to get enough people vaccinated.”

To view the full article, visit https://ibn.fm/Lr4iY

About United Medical Equipment Business Solutions Network Inc.

NOTE TO INVESTORS: The latest news and updates relating to UME are available in the company’s newsroom at https://ibn.fm/UnitedMed

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Predictive Oncology Inc. (NASDAQ: POAI) Taps Its Chairman to be CEO

April 5, 2021 12:31:06

Current POAI Chairman J. Melville (“Mel”) Engle has been appointed to CEO position
Engle has held executive positions throughout his career at leading pharma and medical device companies, including Dey L.P. (a subsidiary of Merck KGaA), Allergan, Anika Therapeutics and Thermogenesis
During his time at Merck’s Dey L.P., Engle transitioned the company from generics to branded products and grew sales from $250 million to $600 million

The world today uses big data for all sorts of predictions, especially consumer behavior. One day, though, big data and technology could prove even more valuable as the catalyst to flip the healthcare script from one that is almost exclusively reactive, to a proactive one that foretells disease at best and eliminates trial and error in therapy decisions after a disease presents at worst. That’s the hope of Predictive Oncology (NASDAQ: POAI), a company using an extensive dataset collected over the last 15 years to better inform individualized cancer therapies today as it advances development of its predictive tumor profiling technology rooted in its artificial intelligence (“AI”) platform.

The company recently named J. Melville (“Mel”) Engle as chief executive officer. Engle has been a director at POAI since October 2016 and has sat as chairman of the board since January 2020. He will take on the top executive role and continue to…

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming Virtual Cell & Gene Meeting on the Mediterranean